KRAS Mutations and Primary Resistance of Lung Adend

PLoS Medicine 2, e17 DOI: 10.1371/journal.pmed.0020017

Citation Report

#	Article	IF	CITATIONS
1	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell, 2005, 8, 287-297.	16.8	372
2	An Update on the Role of Epidermal Growth Factor Receptor Inhibitors in Non–Small Cell Lung Cancer. Seminars in Oncology, 2005, 32, 3-8.	2.2	84
3	Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Journal of Cellular Physiology, 2005, 205, 355-363.	4.1	28
5	Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?. Critical Reviews in Oncology/Hematology, 2005, 55, 67-81.	4.4	24
6	Targeted Therapies for Esophageal Cancer. Oncologist, 2005, 10, 590-601.	3.7	128
7	Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors. Clinical Cancer Research, 2005, 11, 5668-5670.	7.0	27
8	Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain. PLoS Medicine, 2005, 2, e73.	8.4	3,022
9	Gene Mutations in Lung Cancer: Promising Predictive Factors for the Success of Molecular Therapy. PLoS Medicine, 2005, 2, e13.	8.4	24
10	Inhibition of EGFR Signaling: All Mutations Are Not Created Equal. PLoS Medicine, 2005, 2, e377.	8.4	38
11	A Curious Link Between Epidermal Growth Factor Receptor Amplification and Survival: Effect of "Allele Dilution―on Gefitinib Sensitivity?. Journal of the National Cancer Institute, 2005, 97, 621-623.	6.3	22
12	High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 11478-11485.	0.9	135
13	Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology. Journal of Clinical Oncology, 2005, 23, 3227-3234.	1.6	378
14	Erlotinib in the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2005, 5, 767-775.	2.4	21
15	Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. Future Oncology, 2005, 1, 319-322.	2.4	0
16	EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nature Clinical Practice Oncology, 2005, 2, 554-561.	4.3	77
17	Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients. Clinical Cancer Research, 2005, 11, 8686-8698.	7.0	485
18	Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. Journal of the National Cancer Institute, 2005, 97, 1185-1194.	6.3	294
19	Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2005, 10, 855-874.	2.4	8

#	Article	IF	CITATIONS
20	Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer. Clinical Cancer Research, 2005, 11, 6650-6656.	7.0	141
21	Who will benefit from treatment against EGFR?. Lancet Oncology, The, 2005, 6, 257-258.	10.7	13
22	Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology, 2005, 23, 8081-8092.	1.6	608
23	Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas. Journal of Molecular Diagnostics, 2005, 7, 396-403.	2.8	221
24	Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications. Journal of Clinical Oncology, 2005, 23, 3243-3256.	1.6	244
25	Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer. Journal of Clinical Oncology, 2005, 23, 2445-2459.	1.6	676
27	Resistance to epidermal growth factor receptor-targeted therapy. Drug Resistance Updates, 2005, 8, 298-310.	14.4	84
28	Evolving Concepts in the Pathology and Computed Tomography Imaging of Lung Adenocarcinoma and Bronchioloalveolar Carcinoma. Journal of Clinical Oncology, 2005, 23, 3279-3287.	1.6	264
29	Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions. Journal of Clinical Oncology, 2005, 23, 2556-2568.	1.6	579
30	<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. Cancer Research, 2006, 66, 3992-3995.	0.9	2,116
31	Should every lung cancer patient be tested for EGFR mutation?. Expert Opinion on Therapeutic Targets, 2006, 10, 789-791.	3.4	1
32	Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5034-5042.	1.6	701
33	Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 344-350.	1.3	29
34	Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer, 2006, 52, 225-233.	2.0	31
35	Tyrphostins and Other Tyrosine Kinase Inhibitors. Annual Review of Biochemistry, 2006, 75, 93-109.	11.1	205
36	The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy. Clinical Cancer Research, 2006, 12, 5268-5272.	7.0	776
38	Targeting Tyrosine Kinases in Cancer: The Second Wave. Science, 2006, 312, 1175-1178.	12.6	437
39	Bronchioloalveolar Carcinoma: A Review. Clinical Lung Cancer, 2006, 7, 313-322.	2.6	64

#	Article	IF	Citations
40	The New Era in Cancer Research. Science, 2006, 312, 1162-1165.	12.6	278
41	Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2006, 24, 2158-2163.	1.6	143
42	A review of erlotinib and its clinical use. Expert Opinion on Pharmacotherapy, 2006, 7, 177-193.	1.8	74
43	Synchronous multiple primary lung cancers with different response to gefitinib. Lung Cancer, 2006, 53, 245-248.	2.0	17
44	Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: Retrospective analysis of 575 Korean patients. Lung Cancer, 2006, 53, 339-345.	2.0	15
45	Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer, 2006, 54, 201-207.	2.0	35
46	Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non–Small Cell Lung Cancer?. Clinical Cancer Research, 2006, 12, 5919-5920.	7.0	3
47	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Annals of Diagnostic Pathology, 2006, 10, 306-315.	1.3	36
48	Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006, 366, 2-16.	2.2	1,744
49	Epidermal growth factor receptor pathway inhibitors. Update on Cancer Therapeutics, 2006, 1, 299-310.	0.4	6
50	Drugs for Lung Cancer Treatment. Tuberculosis and Respiratory Diseases, 2006, 60, 123.	1.8	0
51	Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Basic Science Discovery with Immediate Clinical Impact. American Journal of the Medical Sciences, 2006, 331, 139-149.	1.1	11
52	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non–Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology, 2006, 1, 52-60.	1.1	6
53	Signal Transduction Therapy for Cancer - Whither Now?. Current Signal Transduction Therapy, 2006, 1, 1-12.	0.5	14
54	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. Journal of Thoracic Oncology, 2006, 1, 965-971.	1.1	19
55	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 2006, 1, S13-S19.	1.1	71
56	Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials, 2006, 1, 1-13.	0.8	44
57	Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor factor receptor inhibitors gefitinib and erlotinib. Anti-Cancer Drugs, 2006, 17, 783-795.	1.4	51

#	Article	IF	CITATIONS
58	Clinical aspects of epidermal growth factor receptor inhibitors: Benefit and risk. Respirology, 2006, 11, 693-698.	2.3	22
59	Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia-Pacific region. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 22-31.	1.1	2
60	A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology, 2006, 48, 779-786.	2.9	21
61	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. British Journal of Cancer, 2006, 94, 896-903.	6.4	132
62	Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Laboratory Investigation, 2006, 86, 981-986.	3.7	80
63	Clinical experience with gefitinib: An update. Critical Reviews in Oncology/Hematology, 2006, 58, 31-45.	4.4	50
64	Prevalence of Mutation in the Epidermal Growth Factor Receptor Gene in Chinese Patients with Non-small Cell Lung Cancer. Clinical Oncology, 2006, 18, 635.	1.4	1
65	Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer and Metastasis Reviews, 2006, 25, 279-292.	5.9	25
66	Biological and clinical implications of EGFR mutations in lung cancer. International Journal of Clinical Oncology, 2006, 11, 190-198.	2.2	194
67	Defining clinically relevant molecular subsets of lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 11-15.	2.3	17
68	Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm. Cancer Chemotherapy and Pharmacology, 2006, 58, 49-53.	2.3	6
69	From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clinical and Translational Oncology, 2006, 8, 71-76.	2.4	17
70	Unraveling molecular markers of biologic therapies in glioma. Current Neurology and Neuroscience Reports, 2006, 6, 185-186.	4.2	0
71	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell, 2006, 9, 485-495.	16.8	427
72	EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans. Cancer Cell, 2006, 9, 421-423.	16.8	47
73	Future Directions in the Second-Line Treatment of Non–Small Cell Lung Cancer. Seminars in Oncology, 2006, 33, 45-51.	2.2	9
74	Optimizing Therapy in Previously Treated Non–Small Cell Lung Cancer. Seminars in Oncology, 2006, 33, 25-31.	2.2	7
75	Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars in Oncology, 2006, 33, 9-16.	2.2	27

	CITATION	Report	
#	Article	IF	CITATIONS
76	Epidermal Growth Factor Receptor Targeting in Cancer. Seminars in Oncology, 2006, 33, 369-385.	2.2	645
77	New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors. Seminars in Oncology, 2006, 33, 407-420.	2.2	242
78	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer, 2006, 6, 295.	2.6	254
79	K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review. Clinical Lung Cancer, 2006, 8, 30-38.	2.6	212
80	Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors. BMC Genomics, 2006, 7, 289.	2.8	66
81	CommonEGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. International Journal of Cancer, 2006, 118, 521-522.	5.1	53
82	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer, 2006, 118, 257-262.	5.1	601
83	Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. International Journal of Cancer, 2006, 119, 727-734.	5.1	20
84	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. Cancer Research, 2006, 66, 11389-11398.	0.9	112
86	Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study. Clinical Cancer Research, 2006, 12, 6049-6055.	7.0	197
87	Social Medicine in the Twenty-First Century. PLoS Medicine, 2006, 3, e445.	8.4	39
88	Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Molecular Cancer Therapeutics, 2006, 5, 2051-2059.	4.1	113
89	Update on <i>Epidermal Growth Factor Receptor</i> Mutations in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 7232-7241.	7.0	357
90	Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels. Clinical Cancer Research, 2006, 12, 7117-7125.	7.0	118
91	Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2006, 12, 839-844.	7.0	688
92	Erlotinib: Optimizing Therapy with Predictors of Response?. Clinical Cancer Research, 2006, 12, 2961-2963.	7.0	20
93	Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors. Genes and Development, 2006, 20, 1496-1510.	5.9	426
94	IGF1R signalling and its inhibition. Endocrine-Related Cancer, 2006, 13, S33-S43.	3.1	231

#	Article	IF	CITATIONS
95	Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib. Clinical Cancer Research, 2006, 12, 5764-5769.	7.0	577
96	Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. Clinical Cancer Research, 2006, 12, 2538-2544.	7.0	245
97	Lung cancer genetics and pharmacogenomics. Cytogenetic and Genome Research, 2006, 115, 298-302.	1.1	2
98	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Annals of Oncology, 2006, 17, ii42-ii45.	1.2	28
99	Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2006, 17, 1120-1127.	1.2	93
100	Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs. Clinical Cancer Research, 2006, 12, 7242-7251.	7.0	324
101	Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 291-323.	6.1	15
102	Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer. Molecular Cancer Research, 2006, 4, 971-981.	3.4	34
103	Current Concepts in Bronchioloalveolar Carcinoma Biology. Clinical Cancer Research, 2006, 12, 3698-3704.	7.0	46
104	Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3915-3921.	7.0	312
105	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics, 2007, 7, 821-836.	3.1	12
106	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19936-19941.	7.1	334
107	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Molecular Cancer Therapeutics, 2007, 6, 515-523.	4.1	26
108	Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma. Molecular Cancer Therapeutics, 2007, 6, 1683-1691.	4.1	249
109	Targeting oncogenic Ras. Genes and Development, 2007, 21, 1989-1992.	5.9	41
110	PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 378-381.	7.0	114
111	Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncologist, 2007, 12, 211-220.	3.7	44
112	Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. Oncologist, 2007, 12, 840-849.	3.7	100

#	Article	IF	CITATIONS
113	Mass Spectrometry to Classify Non–Small-Cell Lung Cancer Patients for Clinical Outcome After Treatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Multicohort Cross-Institutional Study. Journal of the National Cancer Institute, 2007, 99, 838-846.	6.3	303
114	A Translational View of the Molecular Pathogenesis of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 327-343.	1.1	274
115	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Pharmacogenomics, 2007, 8, 1211-1220.	1.3	2
116	Genomic landscapes of cancers: prospects for targeted therapies. Pharmacogenomics, 2007, 8, 1629-1633.	1.3	10
117	Recent advances in targeted therapy for non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2007, 11, 245-257.	3.4	26
118	Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 805-817.	3.3	51
119	Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms. Cancer Research, 2007, 67, 465-473.	0.9	108
120	Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Annals of Oncology, 2007, 18, 447-452.	1.2	41
121	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Molecular Cancer Therapeutics, 2007, 6, 532-541.	4.1	169
122	Schedule-Dependent Cytotoxic Synergism of Pemetrexed and Erlotinib in Human Non–Small Cell Lung Cancer Cells. Clinical Cancer Research, 2007, 13, 3413-3422.	7.0	190
123	PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib. Cancer Research, 2007, 67, 11924-11932.	0.9	674
124	Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib. Journal of Clinical Oncology, 2007, 25, 2528-2533.	1.6	140
125	Targeting of Epidermal Growth Factor Receptor in Patients Affected by Biliary Tract Carcinoma. Journal of Clinical Oncology, 2007, 25, 1145-1145.	1.6	6
126	Pulmonary adenocarcinoma–targeted gene therapy by a cancer- and tissue-specific promoter system. Molecular Cancer Therapeutics, 2007, 6, 244-252.	4.1	19
127	Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 4606s-4612s.	7.0	51
128	Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?. Journal of Clinical Oncology, 2007, 25, 5836-5837.	1.6	6
129	Non-Small Cell Lung Cancer: New Hope for a Chronic Illness. Oncology Nursing Forum, 2007, 34, 963-970.	1.2	8
130	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Molecular Cancer Therapeutics, 2007, 6, 1079-1088,	4.1	30

#	Article	IF	CITATIONS
131	Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis. Journal of Thoracic Oncology, 2007, 2, 1086-1090.	1.1	102
132	P3-160: Histoculture drug response assay for gefitinib in non–small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, S747-S748.	1.1	0
133	Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S68-S76.	1.1	36
134	The Future of Anti-EGFR Therapy. International Journal of Biological Markers, 2007, 22, 88-93.	1.8	2
135	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. International Journal of Biological Markers, 2007, 22, 10-23.	1.8	5
136	Microsatellite and EGFR, HER2 and K-RAS Analyses in Sclerosing Hemangioma of the Lung. American Journal of Surgical Pathology, 2007, 31, 1512-1520.	3.7	36
137	Bronchioloalveolar Lung Cancer. Chest, 2007, 132, 306S-313S.	0.8	51
138	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates, 2007, 10, 81-100.	14.4	74
139	EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiotherapy and Oncology, 2007, 83, 238-248.	0.6	170
140	Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial. Journal of Clinical Oncology, 2007, 25, 2248-2255.	1.6	218
141	Phase II Clinical Trial of Chemotherapy-NaÃ⁻ve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 760-766.	1.6	306
142	Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets, 2007, 11, 1587-1609.	3.4	63
143	<i>KRAS</i> Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 2890-2896.	7.0	597
144	Thérapeutiques ciblées des stades métastatiques. Revue Des Maladies Respiratoires, 2007, 24, 70-72.	1.7	0
145	Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features. Journal of Molecular Diagnostics, 2007, 9, 320-326.	2.8	188
146	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics, 2007, 1, 183-191.	1.6	2
147	Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti–Epidermal Growth Factor Receptor Antibody Therapies. Cancer Research, 2007, 67, 2643-2648.	0.9	801
148	Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab. Journal of Clinical Oncology, 2007, 25, 3230-3237.	1.6	1,109

#	Article	IF	CITATIONS
149	Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. European Respiratory Journal, 2007, 30, 835-839.	6.7	307
150	Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 587-595.	1.6	593
152	Les inhibiteurs de tyrosine kinase de l'EGFR dans le traitement du CBNPC. Revue Des Maladies Respiratoires, 2007, 24, 188-197.	1.7	2
154	Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer. Drugs, 2007, 67, 1125-1138.	10.9	15
155	Dual Inhibition: Combining Epidermal Growth Factor–Targeted Therapies in Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2007, 8, 420-424.	2.6	2
156	Molecular Signatures of Lung Cancer — Toward Personalized Therapy. New England Journal of Medicine, 2007, 356, 76-78.	27.0	71
157	Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4. PLoS ONE, 2007, 2, e426.	2.5	77
158	Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S12-S14.	1.1	6
159	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. International Journal of Cancer, 2007, 120, 1239-1247.	5.1	120
160	Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer, 2007, 110, 599-605.	4.1	97
161	EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy. Oncogene, 2007, 26, 5693-5701.	5.9	76
162	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007, 26, 3291-3310.	5.9	2,421
163	Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 2007, 7, 169-181.	28.4	2,741
164	Lung cancer in never smokers — a different disease. Nature Reviews Cancer, 2007, 7, 778-790.	28.4	1,276
165	Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nature Reviews Drug Discovery, 2007, 6, 871-880.	46.4	153
166	Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. British Journal of Cancer, 2007, 96, 857-863.	6.4	90
167	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation, 2007, 75, 788-799.	1.9	72
168	The epidermal growth factor receptor: from development to tumorigenesis. Differentiation, 2007, 75, 770-787.	1.9	289

#	Article	IF	CITATIONS
169	Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Science, 2007, 98, 357-363.	3.9	48
170	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 2007, 98, 1817-1824.	3.9	554
171	Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 66-78.	1.1	14
172	Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer, 2007, 7, 51.	2.6	76
173	"Who Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?― Current Treatment Options in Oncology, 2007, 8, 28-37.	3.0	18
174	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Internal and Emergency Medicine, 2007, 2, 3-12.	2.0	12
175	Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. Targeted Oncology, 2007, 2, 145-151.	3.6	3
176	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer and Metastasis Reviews, 2008, 27, 387-402.	5.9	26
177	The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cellular and Molecular Life Sciences, 2008, 65, 1566-1584.	5.4	593
178	Molekulardiagnostik von Mutationen des epidermalen Wachstumsfaktor-Rezeptors und Aktivierung nachgeschalteter Signalwege in nichtkleinzelligen Lungenkarzinomen. Onkopipeline, 2008, 1, 101-108.	0.0	0
179	Place des thérapeutiques biologiques ciblées. Oncologie, 2008, 10, 540-544.	0.7	0
180	Reversed mutation rates of <i>KRAS</i> and <i>EGFR</i> genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer, 2008, 113, 3199-3208.	4.1	84
181	EGFR inhibition in the treatment of nonâ€small cell lung cancer. Drug Development Research, 2008, 69, 359-372.	2.9	51
182	Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. Journal of Cellular Biochemistry, 2008, 104, 1124-1149.	2.6	186
183	EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Annals of Oncology, 2008, 19, 717-723.	1.2	243
184	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation, 2008, 48, 113-135.	2.6	20
185	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern Pathology, 2008, 21, S16-S22.	5.5	313
186	The cancer biomarker problem. Nature, 2008, 452, 548-552.	27.8	848

	CITATION	Report	
#	Article	IF	CITATIONS
187	Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455, 1069-1075.	27.8	2,694
188	Molecular diagnosis in oncology. Molecular Biology, 2008, 42, 687-698.	1.3	3
189	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27, 4702-4711.	5.9	1,272
190	The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene, 2008, 27, 5477-5485.	5.9	338
191	Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. British Journal of Cancer, 2008, 99, 923-929.	6.4	204
192	A Sweet New Role for EGFR in Cancer. Cancer Cell, 2008, 13, 375-376.	16.8	40
193	<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 2008, 359, 1757-1765.	27.0	3,353
194	Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer, 2008, 59, 81-87.	2.0	18
195	EGFR FISH versus mutation: Different tests, different end-points. Lung Cancer, 2008, 60, 160-165.	2.0	44
196	Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer, 2008, 62, 193-201.	2.0	46
197	Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer. Lung Cancer, 2008, 62, 236-241.	2.0	9
198	EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients. Onkologie, 2008, 31, 174-178.	0.8	22
199	Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. , 2008, , 224-244.		1
200	Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Human Pathology, 2008, 39, 316-323.	2.0	22
201	EGFR Mutations and EGFR Tyrosine Kinase Inhibition in Non–Small Cell Lung Cancer. Seminars in Oncology Nursing, 2008, 24, 27-33.	1.5	11
202	EGFR Antagonists in Cancer Treatment. New England Journal of Medicine, 2008, 358, 1160-1174.	27.0	1,869
203	Lung Cancer. New England Journal of Medicine, 2008, 359, 1367-1380.	27.0	2,271
204	Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents. Drug Resistance Updates, 2008, 11, 99-109.	14.4	29

#	Article	IF	CITATIONS
205	High-content analysis of cancer genome DNA alterations. Current Opinion in Genetics and Development, 2008, 18, 68-72.	3.3	14
206	Large-Scale Mutagenesis in p19ARF- and p53-Deficient Mice Identifies Cancer Genes and Their Collaborative Networks. Cell, 2008, 133, 727-741.	28.9	167
207	KRAS mutations predict response to EGFR inhibitors. Current Opinion in Pharmacology, 2008, 8, 413-418.	3.5	116
208	Pharmacogenetics: improving drug and dose selection. Current Opinion in Pharmacology, 2008, 8, 639-646.	3.5	20
209	KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Seminars in Diagnostic Pathology, 2008, 25, 288-294.	1.5	16
210	Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008, 26, 4268-4275.	1.6	674
211	First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations. Journal of Clinical Oncology, 2008, 26, 2442-2449.	1.6	812
212	Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer, 2008, 59, 111-118.	2.0	91
213	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, The, 2008, 372, 1809-1818.	13.7	1,248
214	Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib. Journal of Clinical Oncology, 2008, 26, 1472-1478.	1.6	284
215	Molecular genetics of lung cancer in people who have never smoked. Lancet Oncology, The, 2008, 9, 676-682.	10.7	113
216	KRAS Mutations. Journal of Molecular Diagnostics, 2008, 10, 493-495.	2.8	48
217	Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions. Mayo Clinic Proceedings, 2008, 83, 235-250.	3.0	121
218	Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 1626-1634.	1.6	3,032
219	EGFR Mutations in Lung Adenocarcinomas. Journal of Molecular Diagnostics, 2008, 10, 242-248.	2.8	180
220	Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023. Journal of Clinical Oncology, 2008, 26, 2450-2456.	1.6	555
221	Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer. Cancer Research, 2008, 68, 9375-9383.	0.9	235
222	Therapy for Unresectable Metastatic Colorectal Cancer. Seminars in Colon and Rectal Surgery, 2008, 19, 216-225.	0.3	0

#	ARTICLE	IF	CITATIONS
223	Effect of Disrupting Seven-in-Absentia Homolog 2 Function on Lung Cancer Cell Growth. Journal of the National Cancer Institute, 2008, 100, 1606-1629.	6.3	68
224	Signaling networks assembled by oncogenic EGFR and c-Met. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 692-697.	7.1	480
225	Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC. Oncologist, 2008, 13, 1166-1176.	3.7	46
226	Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. Oncologist, 2008, 13, 933-944.	3.7	40
227	Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment. Clinical Cancer Research, 2008, 14, 6867-6876.	7.0	51
228	Frequency and Distinctive Spectrum of <i>KRAS</i> Mutations in Never Smokers with Lung Adenocarcinoma. Clinical Cancer Research, 2008, 14, 5731-5734.	7.0	505
229	Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway. Journal of Thoracic Oncology, 2008, 3, 170-173.	1.1	13
230	Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?. Nature Clinical Practice Oncology, 2008, 5, 10-11.	4.3	1
231	Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opinion on Therapeutic Targets, 2008, 12, 1389-1401.	3.4	16
232	Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers. Clinical Cancer Research, 2008, 14, 6456-6468.	7.0	268
233	Gefitinib Versus Vinorelbine in Chemotherapy-NaÃ⁻ve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study. Journal of Clinical Oncology, 2008, 26, 4253-4260.	1.6	220
234	Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14112-14117.	7.1	113
235	Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers. Clinical Cancer Research, 2008, 14, 6963-6973.	7.0	112
236	Does Gefitinib Shorten Lung Cancer Survival? Chaos Redux. Journal of Clinical Oncology, 2008, 26, 2428-2430.	1.6	10
237	Determinants of <i>RAS</i> istance to Anti–Epidermal Growth Factor Receptor Agents. Journal of Clinical Oncology, 2008, 26, 1582-1584.	1.6	71
238	SpecificEGFRMutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy. Journal of Clinical Oncology, 2008, 26, 2745-2753.	1.6	249
239	The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or) Tj ETQq0 C	0 rgBT /O	verlock 10 Tf

240	Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20864-20869.		7.1	95
-----	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	-----	----

#	Article	IF	CITATIONS
241	The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. Molecular Cancer Therapeutics, 2008, 7, 1251-1257.	4.1	30
242	EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. European Respiratory Journal, 2008, 33, 436-440.	6.7	39
243	A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. Clinical Cancer Research, 2008, 14, 3867-3874.	7.0	73
244	Sensitivity of Normal, Paramalignant, and Malignant Human Urothelial Cells to Inhibitors of the Epidermal Growth Factor Receptor Signaling Pathway. Molecular Cancer Research, 2008, 6, 53-63.	3.4	26
245	A Subset of Lung Adenocarcinomas and Atypical Adenomatous Hyperplasia–Associated Foci Are Genotypically Related. American Journal of Clinical Pathology, 2008, 129, 202-210.	0.7	46
246	TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer. Clinical Cancer Research, 2008, 14, 1182-1191.	7.0	89
247	Newer opportunities in systemic therapy of lung cancer. Annals of Oncology, 2008, 19, vii31-vii37.	1.2	5
248	Requirement of hypoxia-inducible factor-1α down-regulation in mediating the antitumor activity of the anti–epidermal growth factor receptor monoclonal antibody cetuximab. Molecular Cancer Therapeutics, 2008, 7, 1207-1217.	4.1	59
249	Somatic pharmacogenomics in cancer. Pharmacogenomics Journal, 2008, 8, 305-314.	2.0	22
250	Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Annals of Oncology, 2008, 19, 1605-1612.	1.2	81
251	Deregulated <i>EGFR</i> Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops. Cancer Prevention Research, 2008, 1, 156-160.	1.5	80
252	DxS Ltd. Pharmacogenomics, 2008, 9, 463-467.	1.3	24
253	Understanding and re-engineering nucleoprotein machines to cure human disease. Nanomedicine, 2008, 3, 93-105.	3.3	4
254	Highâ€Throughput Lung Cancer Cell Line Screening for Genotypeâ€Correlated Sensitivity to an EGFR Kinase Inhibitor. Methods in Enzymology, 2008, 438, 331-341.	1.0	26
255	Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions. Mayo Clinic Proceedings, 2008, 83, 235-250.	3.0	172
256	Gefitinib Plus Celecoxib in Chemotherapy-NaÃ ⁻ ve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology, 2008, 3, 374-379.	1.1	20
257	A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochemical Journal, 2008, 415, 97-110.	3.7	123
258	Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 111-116.	1.1	248

#	Article	IF	CITATIONS
259	EGFR Inhibitors as First-Line Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 303-310.	1.1	35
260	K-ras as a Target for Lung Cancer Therapy. Journal of Thoracic Oncology, 2008, 3, S160-S163.	1.1	39
261	Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise. Journal of Thoracic Oncology, 2008, 3, 84-93.	1.1	26
262	Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung. Journal of Thoracic Oncology, 2008, 3, 340-347.	1.1	78
263	Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 1003-1011.	1.1	64
264	Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis. American Journal of Surgical Pathology, 2008, 32, 810-827.	3.7	352
265	Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology, 2008, 20, 162-175.	2.4	46
266	Towards a Treatment for RAS-MAPK Pathway Disorders. Monographs in Human Genetics, 2008, , 151-164.	0.5	0
267	Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target. PLoS ONE, 2008, 3, e0001722.	2.5	105
268	Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non–small Cell Lung Cancer. International Journal of Medical Sciences, 2008, 5, 209-217.	2.5	67
269	Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed?. Current Oncology, 2009, 16, 21-25.	2.2	31
270	Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer. Journal of Oncology, 2009, 2009, 1-6.	1.3	6
271	KRAS Mutations in Non-Small Cell Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 201-205.	3.5	474
272	Emerging drugs in the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2009, 14, 311-328.	2.4	13
273	Small-molecule inhibitors of the human epidermal receptor family. Expert Opinion on Investigational Drugs, 2009, 18, 1829-1842.	4.1	25
274	Micropapillary Histology. American Journal of Clinical Pathology, 2009, 131, 615-617.	0.7	7
275	Impact of Epidermal Growth Factor Receptor and <i>KRAS</i> Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials. Clinical Cancer Research, 2009, 15, 5267-5273.	7.0	382
276	Genetic Abnormalities of the <i>EGFR</i> Pathway in African American Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 5620-5626.	1.6	85

#	Article	IF	CITATIONS
277	Integration of Molecular Profiling into the Lung Cancer Clinic. Clinical Cancer Research, 2009, 15, 5317-5322.	7.0	82
278	Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Non—Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. International Journal of Surgical Pathology, 2009, 17, 206-218.	0.8	84
279	Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Molecular Cancer Therapeutics, 2009, 8, 2526-2536.	4.1	65
280	Mutations and Response to Epidermal Growth Factor Receptor Inhibitors: Fig. 1 Clinical Cancer Research, 2009, 15, 1133-1139.	7.0	120
281	Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 137-144.	3.2	21
282	Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opinion on Therapeutic Targets, 2009, 13, 339-362.	3.4	77
283	Current Treatments for Advanced Stage Non-Small Cell Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 233-241.	3.5	130
284	<i>EGFR/KRAS/BRAF</i> Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases. Clinical Cancer Research, 2009, 15, 4554-4560.	7.0	258
285	Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas. Clinical Cancer Research, 2009, 15, 6790-6799.	7.0	176
286	Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, S1029-S1039.	1.1	41
287	Sensitivity and resistance to EGF-R inhibitors. MAbs, 2009, 1, 590-599.	5.2	5
288	Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives. Cancer Biology and Therapy, 2009, 8, 206-212.	3.4	10
289	Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines. Journal of Thoracic Oncology, 2009, 4, 161-166.	1.1	59
290	Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer. Molecular Cancer Therapeutics, 2009, 8, 3296-3306.	4.1	58
291	Theme: Oncology - Molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. Biomarkers in Medicine, 2009, 3, 139-151.	1.4	4
292	K- <i>RAS</i> mutation in the screening, prognosis and treatment of cancer. Biomarkers in Medicine, 2009, 3, 757-769.	1.4	34
293	Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Molecular Cancer Therapeutics, 2009, 8, 1536-1546.	4.1	24
294	Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines. PLoS ONE, 2009, 4, e4576.	2.5	177

#	Article	IF	CITATIONS
295	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Annals of Oncology, 2009, 20, 298-304.	1.2	286
296	Sorafenib Inhibits Non–Small Cell Lung Cancer Cell Growth by Targeting B-RAF in KRAS Wild-Type Cells and C-RAF in KRAS Mutant Cells. Cancer Research, 2009, 69, 6515-6521.	0.9	84
297	<i>EML4-ALK</i> : Honing In on a New Target in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 4232-4235.	1.6	313
298	EGFR-targeted therapies in lung cancer: predictors of response and toxicity. Pharmacogenomics, 2009, 10, 59-68.	1.3	67
299	The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Oncologist, 2009, 14, 1116-1130.	3.7	57
300	Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring <i>K-RAS</i> Mutations. Cancer Research, 2009, 69, 7644-7652.	0.9	138
301	Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance. Clinical Cancer Research, 2009, 15, 3484-3494.	7.0	297
302	Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis. Cancer Prevention Research, 2009, 2, 330-337.	1.5	36
303	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 6852-6861.	7.0	105
304	Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. Journal of Clinical Oncology, 2009, 27, 5650-5659.	1.6	115
305	<i>EGFR</i> and K- <i>ras</i> Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors. American Journal of Clinical Pathology, 2009, 131, 478-489.	0.7	67
306	Implementation of Novel Pyrosequencing Assays to Screen for Common Mutations of BRAF and KRAS in a Cohort of Sporadic Colorectal Cancers. Diagnostic Molecular Pathology, 2009, 18, 62-71.	2.1	48
307	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Annals of Oncology, 2009, 20, 213-226.	1.2	37
308	Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. Cancer Research, 2009, 69, 7088-7095.	0.9	23
309	Pathogenesis of lung cancer signalling pathways: roadmap for therapies. European Respiratory Journal, 2009, 33, 1485-1497.	6.7	151
310	Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2009, 4, 12-21.	1.1	75
311	KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncology, 2009, 45, 826-829.	1.5	21
312	A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer. BMC Cancer, 2009, 9, 145.	2.6	26

	CITATIO	CITATION REPORT	
#	Article	IF	CITATIONS
313	Targeting the EGFR and the PKB pathway in cancer. Current Opinion in Cell Biology, 2009, 21, 185-193.	5.4	64
314	Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. Clinical Lung Cancer, 2009, 10, 13-19.	2.6	1
315	Drugâ€regulatable cancer cell death induced by BID under control of the tissueâ€specific, lung cancerâ€targeted TTS promoter system. International Journal of Cancer, 2009, 125, 1975-1984.	5.1	7
316	EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: Implications for antiâ€EGFR treatment of a rare lung malignancy. International Journal of Cancer, 2009, 125, 2479-2482.	5.1	103
317	Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer, 2009, 115, 1518-1530.	4.1	20
318	EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. Journal of Cancer Research and Clinical Oncology, 2009, 135, 771-782.	2.5	38
319	Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1647-1654.	2.5	69
320	Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1137-1148.	2.5	39
321	Resistance mechanisms of tumour cells to EGFR inhibitors. Clinical and Translational Oncology, 2009, 11, 270-275.	2.4	19
322	Translational research in phase I trials. Clinical and Translational Oncology, 2009, 11, 580-588.	2.4	4
323	Histoculture drug response assay for gefitinib in non-small-cell lung cancer. General Thoracic and Cardiovascular Surgery, 2009, 57, 138-143.	0.9	13
324	Translating genomics into clinical practice: Applications in lung cancer. Current Oncology Reports, 2009, 11, 263-268.	4.0	5
325	Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Targeted Oncology, 2009, 4, 267-273.	3.6	20
326	Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. Targeted Oncology, 2009, 4, 311-322.	3.6	3
327	Pulmonary preneoplasia – sequential molecular carcinogenetic events. Histopathology, 2009, 54, 43-54.	2.9	88
328	GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. Modern Pathology, 2009, 22, 718-724.	5.5	86
329	Outpacing Cancer. Nature Medicine, 2009, 15, 718-722.	30.7	2
330	Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene, 2009, 28, S4-S13.	5.9	62

#	Article	IF	CITATIONS
331	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene, 2009, 28, S14-S23.	5.9	179
332	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 2009, 28, S24-S31.	5.9	799
333	Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients. British Journal of Cancer, 2009, 100, 145-152.	6.4	39
334	Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. British Journal of Cancer, 2009, 100, 985-992.	6.4	56
335	Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. British Journal of Cancer, 2009, 100, 1257-1266.	6.4	87
336	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6251-6266.	1.6	732
337	Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i> . Journal of Clinical Oncology, 2009, 27, 4247-4253.	1.6	1,775
338	Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treatment Reviews, 2009, 35, 167-174.	7.7	50
339	The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resistance Updates, 2009, 12, 95-102.	14.4	56
340	Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non–small cell lung carcinomas. Human Pathology, 2009, 40, 1152-1158.	2.0	171
341	Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer, 2009, 64, 314-318.	2.0	93
342	Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer, 2009, 65, 355-362.	2.0	73
343	Individualizing Therapy for Non–Small-Cell Lung Cancer: A Paradigm Shift from Empiric to Integrated Decision-Making. Clinical Lung Cancer, 2009, 10, 148-150.	2.6	23
344	The Role of Cetuximab in the Management of Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2009, 10, 230-238.	2.6	11
345	Gefitinib for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2009, 9, 17-35.	2.4	46
346	Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer. Journal of Molecular Diagnostics, 2009, 11, 381-389.	2.8	9
347	Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones. Neoplasia, 2009, 11, 1084-1092.	5.3	92
348	Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer. Journal of the National Cancer Institute, 2009, 101, 1308-1324.	6.3	486

#	Article	IF	CITATIONS
349	Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. Journal of Clinical Pathology, 2009, 62, 1096-1102.	2.0	65
350	Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6229-6236.	1.6	93
352	Quel traitement en deuxième ligne métastatique des cancers bronchiques non à petites cellules ?. Revue Des Maladies Respiratoires Actualites, 2009, 1, 415-420.	0.0	0
353	Non–Small Cell Lung Carcinoma. , 2009, 14, 199-205.		2
354	EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort. Journal of Thoracic Oncology, 2009, 4, 318-325.	1.1	52
355	MYC and EIF3H Coamplification Significantly Improve Response and Survival of Non-small Cell Lung Cancer Patients (NSCLC) Treated with Gefitinib. Journal of Thoracic Oncology, 2009, 4, 472-478.	1.1	50
356	BRAF ^{V600E} mutation in papillary thyroid carcinoma: a potential target for therapy?. Expert Review of Endocrinology and Metabolism, 2009, 4, 467-480.	2.4	0
357	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Anti-Cancer Drugs, 2010, 21, 151-168.	1.4	9
358	Metastatic Pancreatic Adenocarcinoma: Current Standards, Future Directions. American Journal of Therapeutics, 2010, 17, 79-85.	0.9	1
359	Somatic mutations affect key pathways in lung adenocarcinoma. Yearbook of Pulmonary Disease, 2010, 2010, 115-117.	0.4	0
360	De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 399-400.	1.1	74
361	Advances in the diagnosis of lung cancer: contribution of molecular biology to bronchoscopic diagnosis. Current Opinion in Pulmonary Medicine, 2010, 16, 315-320.	2.6	11
362	Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status. Journal of Thoracic Oncology, 2010, 5, 591-596.	1.1	69
363	Genetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1887-1893.	1.1	31
364	Recent Development of Molecular-Targeted Drugs in Lung Cancer. Internal Medicine, 2010, 49, 1923-1934.	0.7	6
365	Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1623-1629.	1.1	92
366	Synchronous EGFR and KRAS mutations in non-small cell lung carcinoma. Pathology, 2010, 42, S69.	0.6	0
367	A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular Features, and Possible Pitfalls in Routine Practice. Journal of Thoracic Oncology, 2010, 5, 830-836.	1.1	76

#	Article	IF	CITATIONS
368	Epigenetic Inactivation of the Thyroid Hormone Receptor \hat{I}^21 Gene at 3p24.2 in Lung Cancer. Annals of Surgical Oncology, 2010, 17, 2222-2228.	1.5	32
370	Targeted Inhibition of Kinases in Cancer Therapy. Mount Sinai Journal of Medicine, 2010, 77, 573-586.	1.9	34
371	Personalized Medicine in Non–Small-Cell Lung Cancer: Is <i>KRAS</i> a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?. Journal of Clinical Oncology, 2010, 28, 4769-4777.	1.6	243
372	Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 1023-1028.	2.3	25
374	Molecular Testing in Lung Cancer: The Time Is Now. Current Oncology Reports, 2010, 12, 335-348.	4.0	22
375	Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer and Metastasis Reviews, 2010, 29, 37-48.	5.9	81
376	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer and Metastasis Reviews, 2010, 29, 49-60.	5.9	191
377	Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Investigational New Drugs, 2010, 28, 791-799.	2.6	67
378	KRAS gene mutations in lung cancer: Particulars established and issues unresolved. Pathology International, 2010, 60, 651-660.	1.3	40
379	Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 257-263.	2.6	8
380	Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer. Biochemical Pharmacology, 2010, 80, 613-623.	4.4	83
381	Somatic mutations of signaling genes in non-small-cell lung cancer. Cancer Genetics and Cytogenetics, 2010, 203, 7-15.	1.0	40
382	Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Molecular Medicine, 2010, 2, 146-158.	6.9	370
383	Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmallâ€cell lung cancer. Cancer, 2010, 116, 1336-1343.	4.1	99
384	<i>KRAS</i> mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer, 2010, 116, 2682-2687.	4.1	67
385	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116, 5599-5607.	4.1	143
386	<i>KRAS</i> mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Molecular Carcinogenesis, 2010, 49, 353-362.	2.7	116
387	EGFR/Met association regulates EGFR TKI resistance in breast cancer. Journal of Molecular Signaling, 2010, 5, 8.	0.5	78

#	Article	IF	Citations
388	Contribution of BCR–ABLâ€independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Science, 2010, 101, 137-142.	3.9	27
389	Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutationâ€ŧargeted lung cancer therapy. Cancer Science, 2010, 101, 1933-1938.	3.9	8
390	Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene, 2010, 29, 4625-4635.	5.9	125
391	E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases. Oncogene, 2010, 29, 2760-2771.	5.9	64
392	Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas. Nature Biotechnology, 2010, 28, 71-78.	17.5	71
393	Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer, 2010, 10, 130-137.	28.4	618
394	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 2010, 10, 760-774.	28.4	943
395	Refining the treatment of advanced nonsmall cell lung cancer. Lung Cancer: Targets and Therapy, 2010, 1, 9.	2.7	1
396	Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2010, 1, 37.	2.7	0
397	EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 2010, 1, 497-514.	1.8	159
398	Prevention of Lung Cancer: Future Perspective with Natural Compounds. Tuberculosis and Respiratory Diseases, 2010, 69, 1.	1.8	6
399	Drug resistance in lung cancer. Lung Cancer: Targets and Therapy, 0, , 23.	2.7	40
400	Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Annals of Oncology, 2010, 21, 1385-1387.	1.2	10
401	Identification of Common Predictive Markers of <i>In vitro</i> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines. Molecular Cancer Therapeutics, 2010, 9, 1985-1994.	4.1	59
402	Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis, 2010, 31, 577-586.	2.8	158
403	Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations. Cancer Research, 2010, 70, 3843-3850.	0.9	55
404	Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 3076-3083.	1.6	402
405	Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 1938-1949.	7.0	112

#	Article	IF	CITATIONS
406	Concordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem studyâ~†. European Journal of Cardio-thoracic Surgery, 2010, 38, 34-37.	1.4	14
407	PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541. Neuro-Oncology, 2010, 12, 967-975.	1.2	31
408	Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. Endocrine-Related Cancer, 2010, 17, 623-636.	3.1	59
409	Thymoma and thymic carcinoma. European Journal of Cardio-thoracic Surgery, 2010, 37, 13-25.	1.4	163
410	A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development. Clinical Cancer Research, 2010, 16, 4647-4653.	7.0	104
411	Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies. Science Signaling, 2010, 3, ra67.	3.6	131
412	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. Cancer Investigation, 2010, 28, 413-423.	1.3	21
413	Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nature Reviews Clinical Oncology, 2010, 7, 493-507.	27.6	593
414	EGF receptor in lung cancer: a successful story of targeted therapy. Expert Review of Anticancer Therapy, 2010, 10, 1577-1587.	2.4	12
415	Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2010, 10, 1589-1599.	2.4	8
416	Potential Clinical Significance of a Plasma-Based KRAS Mutation Analysis in Patients with Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2010, 16, 1324-1330.	7.0	100
417	Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. DMM Disease Models and Mechanisms, 2010, 3, 111-119.	2.4	77
418	New and potential clinical applications ofKRASas a cancer biomarker. Expert Opinion on Medical Diagnostics, 2010, 4, 383-395.	1.6	7
419	Strategies for Prolonged Therapy in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5116-5123.	1.6	64
420	Should we continue to use the term non-small-cell lung cancer?. Annals of Oncology, 2010, 21, vii225-vii229.	1.2	35
421	The Role of Irreversible EGFR Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Overcoming Resistance to Reversible EGFR Inhibitors. Cancer Investigation, 2010, 28, 413-423.	1.3	35
422	Free circulating nucleic acids in plasma and serum (CNAPS) – Useful for the detection of lung cancer patients?. Cancer Biomarkers, 2010, 6, 211-219.	1.7	27
423	HER Kinase Axis Receptor Dimer Partner Switching Occurs in Response to EGFR Tyrosine Kinase Inhibition despite Failure to Block Cellular Proliferation. Cancer Research, 2010, 70, 1989-1999.	0.9	63

#	Article	IF	CITATIONS
424	Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 358-365.	2.5	61
425	Novel insights into the molecular origins and treatment of lung cancer. Cell Cycle, 2010, 9, 4098-4105.	2.6	19
426	Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. Oncology, 2010, 79, 78-84.	1.9	14
427	Differential Contribution to Neuroendocrine Tumorigenesis of Parallel Egfr Signaling in Cancer Cells and Pericytes. Genes and Cancer, 2010, 1, 125-141.	1.9	21
428	Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biology and Therapy, 2010, 9, 572-582.	3.4	59
429	Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers. Journal of Thoracic Oncology, 2010, 5, 1734-1740.	1.1	90
430	Use of Epidermal Growth Factor Receptor/Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Mutation Testing to Define Clonal Relationships Among Multiple Lung Adenocarcinomas. Chest, 2010, 137, 46-52.	0.8	92
431	Prospects for molecular staging of non-small-cell lung cancer from genomic alterations. Expert Review of Respiratory Medicine, 2010, 4, 499-508.	2.5	8
433	KRAS Mutation. Journal of Molecular Diagnostics, 2010, 12, 43-50.	2.8	102
434	Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion. Journal of Medicinal Chemistry, 2010, 53, 2038-2050.	6.4	49
435	Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers. Lung Cancer, 2010, 67, 355-360.	2.0	76
436	Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer, 2010, 68, 198-203.	2.0	105
437	KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies. Lung Cancer, 2010, 69, 272-278.	2.0	289
438	New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer, 2010, 69, 1-12.	2.0	59
439	Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. Lung Cancer, 2010, 69, 259-264.	2.0	19
440	Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology, 2010, 7, 401-414.	27.6	231
441	Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Molecular Cancer, 2010, 9, 75.	19.2	197
442	Usefulness of Peptide Nucleic Acid (PNA)-Clamp Smart Amplification Process Version 2 (SmartAmp2) for Clinical Diagnosis of KRAS Codon12 Mutations in Lung Adenocarcinoma. Journal of Molecular Diagnostics, 2010, 12, 118-124.	2.8	33

#	Article	IF	CITATIONS
443	A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Human Pathology, 2010, 41, 94-102.	2.0	81
444	EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Human Pathology, 2010, 41, 1053-1060.	2.0	24
445	Mucinous adenocarcinoma of the lung in association with congenital pulmonary airway malformation. Journal of Pediatric Surgery, 2010, 45, 2256-2259.	1.6	41
446	Molecular networks in respiratory epithelium carcinomas. Cancer Letters, 2010, 295, 1-6.	7.2	0
447	Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer, 2010, 46, 2166-2177.	2.8	71
448	Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treatment Reviews, 2010, 36, S21-S29.	7.7	128
449	Clinical Applications of Kinase Inhibitors in Solid Tumors. , 2010, , 615-631.		1
450	Krüppel-Like Factor 5 Is Not Required for K-RasG12D Lung Tumorigenesis, but Represses ABCG2 Expression and Is Associated with Better Disease-Specific Survival. American Journal of Pathology, 2010, 177, 1503-1513.	3.8	18
451	Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer, 2010, 69, 110-115.	2.0	83
452	Association of Polymorphisms in∢i>AKT1and <i>EGFR</i> with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib. Molecular Cancer Therapeutics, 2010, 9, 581-593.	4.1	67
453	Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 918-927.	1.6	263
454	Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial. Journal of Clinical Oncology, 2010, 28, 744-752.	1.6	489
455	18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis. Lung Cancer, 2010, 67, 76-80.	2.0	66
456	Mutation Detection of Epidermal Growth Factor Receptor and KRAS Genes Using the Smart Amplification Process Version 2 from Formalin-Fixed, Paraffin-Embedded Lung Cancer Tissue. Journal of Molecular Diagnostics, 2010, 12, 257-264.	2.8	38
457	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. Cancer Research, 2010, 70, 5901-5911.	0.9	245
459	Favorable Response to Erlotinib in a Lung Adenocarcinoma With Both Epidermal Growth Factor Receptor Exon 19 Deletion and <i>K-ras</i> G13D Mutations. Journal of Clinical Oncology, 2010, 28, e111-e112.	1.6	16
460	Cetuximab in the treatment of patients with colorectal cancer. Expert Opinion on Biological Therapy, 2011, 11, 937-949.	3.1	48
461	Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations. Journal of Clinical Oncology, 2011, 29, 2046-2051.	1.6	616

#	Article	IF	CITATIONS
462	¹⁸ F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Journal of Nuclear Medicine, 2011, 52, 1684-1689.	5.0	94
463	Targeted Therapies for Thymic Malignancies. Thoracic Surgery Clinics, 2011, 21, 115-123.	1.0	9
464	Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine, 2011, 32, 703-740.	2.1	194
466	Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer, 2011, 73, 195-202.	2.0	96
467	High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer, 2011, 74, 384-391.	2.0	10
468	Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer, 2011, 74, 355-363.	2.0	22
469	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs, 2011, 71, 2231-2246.	10.9	23
470	Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. Journal of Experimental and Clinical Cancer Research, 2011, 30, 30.	8.6	77
471	Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome. Translational Oncology, 2011, 4, 59-70.	3.7	11
472	The landscape of <i>EGFR</i> pathways and personalized management of non-small-cell lung cancer. Future Oncology, 2011, 7, 519-541.	2.4	47
473	Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment. American Journal of Pathology, 2011, 178, 1940-1948.	3.8	42
474	Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treatment Reviews, 2011, 37, 456-64.	7.7	69
475	Exon scanning by reverse transcriptase–polymerase chain reaction for detection of known and novel EML4–ALK fusion variants in non–small cell lung cancer. Cancer Genetics, 2011, 204, 45-52.	0.4	84
476	Dissecting the effect of targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in human hepatocellular carcinoma cells. Journal of Hepatology, 2011, 55, 351-358.	3.7	48
477	Systemic treatment of non-small-cell lung cancer. European Journal of Cancer, 2011, 47, S375-S377.	2.8	6
478	Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncology, The, 2011, 12, 1169-1174.	10.7	165
479	Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology, 2011, 18, 424-436.	2.5	37
480	Epidermal growth factor receptor mutationâ€guided treatment for lung cancers: Where are we now?. Thoracic Cancer, 2011, 2, 1-6.	1.9	5

#	Article	IF	CITATIONS
481	Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8773-8778.	7.1	213
482	Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Frontiers in Bioscience - Landmark, 2011, 16, 116.	3.0	8
483	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma. Journal of Clinical Investigation, 2011, 121, 1313-1328.	8.2	141
484	From Clinical Trials to Clinical Practice: Predictors of Response to Erlotinib in Advanced Non-Small Cell Lung Cancer Patients Pretreated with Chemotherapy. Tumori, 2011, 97, 160-165.	1.1	10
485	Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer. International Journal of Proteomics, 2011, 2011, 1-13.	2.0	21
486	Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS ONE, 2011, 6, e19601.	2.5	107
487	Reply to M.C. Garassino et al. Journal of Clinical Oncology, 2011, 29, 3837-3837.	1.6	0
488	IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Research, 2011, 21, 44-56.	1.2	18
489	Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 707-715.	1.1	160
490	Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America. Journal of Thoracic Oncology, 2011, 6, 1955-1959.	1.1	113
491	Yin Yang-1(YY-1) expression in idiopathic pulmonary fibrosis. Journal of Receptor and Signal Transduction Research, 2011, 31, 188-191.	2.5	2
492	A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations. Journal of Thoracic Oncology, 2011, 6, 1435-1437.	1.1	131
493	Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans. Journal of Thoracic Oncology, 2011, 6, 28-31.	1.1	126
494	NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-32.	4.9	227
495	Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology, 2011, 59, 1204-1214.	2.9	40
496	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nature Medicine, 2011, 17, 304-312.	30.7	94
497	Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 476-480.	0.8	40
498	Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive. Expert Review of Respiratory Medicine, 2011, 5, 413-424.	2.5	24

		CITATION REPORT		
#	Article		IF	CITATIONS
499	EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 201	1, 6, 49-69.	22.4	644
500	Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. European Respiratory Journal, 2011, 37, 183-193.		6.7	37
501	Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tum A Tool for Noninvasive Monitoring of Tumor Response to Therapy. Molecular Imaging and Bio 2011, 13, 940-948.	or Burden: blogy,	2.6	51
502	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human no lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Onco 2011, 137, 1397-1408.	n–small logy,	2.5	17
507	Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs). Clinical and Trar Oncology, 2011, 13, 812-818.	NSCLC) Islational	2.4	7
508	Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung can patients treated with adjuvant chemotherapy. Tumor Biology, 2011, 32, 381-390.	cer	1.8	30
509	Genetically informed lung cancer medicine. Journal of Pathology, 2011, 223, 231-241.		4.5	59
510	Clinical cancer genomics: how soon is now?. Journal of Pathology, 2011, 223, 319-327.		4.5	34
511	KRAS and BRAF: drug targets and predictive biomarkers. Journal of Pathology, 2011, 223, 22	0-230.	4.5	133
512	Somatic mutation of fibroblast growth factor receptorâ€3 (<i>FGFR3</i>) defines a distinct morphological subtype of highâ€grade urothelial carcinoma. Journal of Pathology, 2011, 224	r, 270-279.	4.5	73
513	Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Jo Surgical Oncology, 2011, 103, 574-586.	ournal of	1.7	21
514	Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR si pathways. Journal of Cellular Physiology, 2011, 226, 2762-2781.	gnaling	4.1	147
515	<i>EGFR</i> and <i>KRAS</i> mutations in lung carcinoma. Cancer Cytopathology, 2011, 11	.9, 111-117.	2.4	213
516	Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology, 2011,	78, 227-242.	4.4	33
517	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Example. Annals of Pharmacotherapy, 2011, 45, 263-275.	Case	1.9	0
518	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase In and New Therapeutic Perspectives in Non Small Cell Lung Cancer. Current Drug Targets, 201 922-933.	hibitors 1, 12,	2.1	25
519	Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteir Portion. Mini-Reviews in Medicinal Chemistry, 2011, 11, 1019-1030.	ie-Trap	2.4	37
520	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.		2.0	91

	CITAI	ON REPORT	
#	Article	IF	CITATIONS
521	EGFR Mutant Lung Cancer. Current Topics in Microbiology and Immunology, 2011, 355, 59-81.	1.1	8
522	Genotype-driven therapies for non-small cell lung cancer: focus on <i>EGFR</i> , <i>KRAS</i> and <i>ALK</i> gene abnormalities. Therapeutic Advances in Medical Oncology, 2011, 3, 113-125.	3.2	96
523	Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 4574-4580.	1.6	122
524	Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. Expert Review of Anticancer Therapy, 2011, 11, 1587-1597.	2.4	15
525	Bexarotene Plus Erlotinib Suppress Lung Carcinogenesis Independent of <i>KRAS</i> Mutations in Two Clinical Trials and Transgenic Models. Cancer Prevention Research, 2011, 4, 818-828.	1.5	50
526	Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics, 2011, 10, 806-816.	4.1	144
527	Emerging Concepts in the Pathology and Molecular Biology of Advanced Non–Small Cell Lung Cancer. American Journal of Clinical Pathology, 2011, 136, 228-238.	0.7	43
528	Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects. Oncologist, 2011, 16, 1006-1020.	3.7	13
529	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	1.1	4,127
530	Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy: Open Access in Clinical Medicine, 2011, 8, 15-22.	0.2	6
531	Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing. Journal of Thoracic Oncology, 2011, 6, 451-458.	1.1	230
532	Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1603-1608.	7.1	89
533	Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. British Journal of Cancer, 2011, 105, 1-8.	6.4	52
534	Effect of Predictive Performance of a Biomarker for the Sample Size of Targeted Designs for Randomized Clinical Trials. Statistics in Biopharmaceutical Research, 2011, 3, 536-548.	0.8	1
535	Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-7.	3.0	108
536	Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2011, 12, 8530-8538.	4.1	4
537	Drug Resistance and Its Significance for Treatment Decisions in Non-Small-Cell Lung Cancer. Current Oncology, 2012, 19, 45-51.	2.2	75
538	LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort. Drug Discoveries and Therapeutics, 2012, , .	1.5	5

#	Article	IF	CITATIONS
539	Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmacogenomics and Personalized Medicine, 2012, 5, 113.	0.7	18
540	Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib. Clinical Medicine Insights: Oncology, 2012, 6, CMO.S7340.	1.3	32
541	KRAS Wild-Type Lung Cancer: A Moving Target in an Era of Genotype Migration. Journal of Clinical Oncology, 2012, 30, 3322-3324.	1.6	9
542	Twist1 Suppresses Senescence Programs and Thereby Accelerates and Maintains Mutant Kras-Induced Lung Tumorigenesis. PLoS Genetics, 2012, 8, e1002650.	3.5	86
543	Personalized Targeted Therapy for Lung Cancer. International Journal of Molecular Sciences, 2012, 13, 11471-11496.	4.1	61
544	Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib. Molecular Cancer Therapeutics, 2012, 11, 2633-2643.	4.1	97
545	Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1315-1326.	1.1	175
546	Personalized management of patients with solid cancers. Current Opinion in Oncology, 2012, 24, 297-304.	2.4	16
547	IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Imaging, 2012, 27, 340-353.	1.5	69
548	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2012, 30, 3337-3344.	1.6	247
549	Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> -Mutant Cancers. Clinical Cancer Research, 2012, 18, 6169-6177.	7.0	503
550	Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?. Genes and Cancer, 2012, 3, 467-480.	1.9	116
551	Of mice and men: a comparative study of cancer-associated fibroblasts in mammary carcinoma. Upsala Journal of Medical Sciences, 2012, 117, 196-201.	0.9	7
552	EGFR and KRAS mutation analysis in cytologic samples of lung adenocarcinoma enabled by laser capture microdissection. Modern Pathology, 2012, 25, 548-555.	5.5	73
553	Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Current Medical Research and Opinion, 2012, 28, 1699-1708.	1.9	10
554	The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers. Molecular Therapy, 2012, 20, 749-758.	8.2	231
555	Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Research, 2012, 22, 1197-1211.	5.5	461
556	Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity. Cancer Biology and Therapy, 2012, 13, 369-378.	3.4	22

#	Article	IF	CITATIONS
557	MEK1/2 Inhibition Elicits Regression of Autochthonous Lung Tumors Induced by KRASG12D or BRAFV600E. Cancer Research, 2012, 72, 3048-3059.	0.9	48
558	Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo. Molecular Cancer Therapeutics, 2012, 11, 1884-1893.	4.1	4
559	Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a <i>KRAS</i> Mutation or <i>FGFR1</i> Gene Amplification. Molecular Cancer Therapeutics, 2012, 11, 2301-2305.	4.1	22
560	Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Science Translational Medicine, 2012, 4, 120ra17.	12.4	1,138
561	Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemotherapy Research and Practice, 2012, 2012, 1-9.	1.6	59
562	Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer. Biochemistry Research International, 2012, 2012, 1-18.	3.3	42
563	Research progress on criteria for discontinuation of EGFR inhibitor therapy. OncoTargets and Therapy, 2012, 5, 263.	2.0	5
564	EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy. Journal of Thoracic Oncology, 2012, 7, 672-680.	1.1	28
565	Clinical and Pathological Characteristics, Outcome and Mutational Profiles Regarding Non–Small-Cell Lung Cancer Related to Wood-Smoke Exposure. Journal of Thoracic Oncology, 2012, 7, 1228-1234.	1.1	48
566	Semiautomated Laser Capture Microdissection of Lung Adenocarcinoma Cytology Samples. Acta Cytologica, 2012, 56, 622-631.	1.3	17
567	Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology, 2012, 41, 1751-1761.	3.3	14
568	Treatment of nonsmall cell lung cancer. Current Opinion in Oncology, 2012, 24, 123-129.	2.4	25
569	Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. International Journal of Oncology, 2012, 41, 147-52.	3.3	15
570	Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. Journal of Thoracic Oncology, 2012, 7, 1815-1822.	1.1	160
571	First- and second-line treatment of non-small-cell lung cancer patients withEGFRmutation-positive tumors. Lung Cancer Management, 2012, 1, 201-217.	1.5	0
572	Rare and Novel Epidermal Growth Factor Receptor Mutations in Non—Small-Cell Lung Cancer and Lack of Clinical Response to Gefitinib in Two Cases. Journal of Thoracic Oncology, 2012, 7, 941-942.	1.1	11
573	Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. British Journal of Cancer, 2012, 106, 1648-1659.	6.4	38
574	Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer, 2012, 78, 201-206.	2.0	32

#	Article	IF	CITATIONS
575	Mechanisms of intrinsic and acquired resistance to kinaseâ€ŧargeted therapies. Pigment Cell and Melanoma Research, 2012, 25, 819-831.	3.3	43
576	The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer, 2012, 76, 131-137.	2.0	26
577	Role of molecular studies in the diagnosis of lung adenocarcinoma. Modern Pathology, 2012, 25, S11-S17.	5.5	22
578	Molecular Profiling to Optimize Treatment in Non-Small Cell Lung Cancer: A Review of Potential Molecular Targets for Radiation Therapy by the Translational Research Program of the Radiation Therapy Oncology Group. International Journal of Radiation Oncology Biology Physics, 2012, 83, e453-e464.	0.8	34
579	The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Investigational New Drugs, 2012, 30, 2148-2160.	2.6	15
580	Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell, 2012, 150, 1107-1120.	28.9	1,591
581	Molecular Markers for Incidence, Prognosis, and Response to Therapy. Surgical Oncology Clinics of North America, 2012, 21, 161-175.	1.5	8
582	A Virtual Pyrogram Generator to Resolve Complex Pyrosequencing Results. Journal of Molecular Diagnostics, 2012, 14, 149-159.	2.8	21
583	Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer. , 2012, , .		0
584	A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers. Molecular BioSystems, 2012, 8, 1553.	2.9	33
585	Vandetanib for the treatment of lung cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1211-1221.	4.1	6
586	Targeted therapy of non-small-cell lung carcinoma. Therapeutic Advances in Respiratory Disease, 2012, 6, 41-56.	2.6	4
587	High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma. Clinical Cancer Research, 2012, 18, 1760-1768.	7.0	60
588	Translating genomic information into clinical medicine: Lung cancer as a paradigm. Genome Research, 2012, 22, 2101-2108.	5.5	74
589	Impact of Genomics on Personalized Cancer Medicine. Clinical Cancer Research, 2012, 18, 612-618.	7.0	52
590	Hotspot oncomutations: implications for personalized cancer treatment. Expert Review of Molecular Diagnostics, 2012, 12, 603-620.	3.1	13
591	Prediction in the face of uncertainty: A Monte Carlo-based approach for systems biology of cancer treatment. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2012, 746, 163-170.	1.7	29
592	Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Medicine, 2012, 10, 28.	5.5	109

#	Article	IF	Citations
593	KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer, 2012, 107, 1997-2004.	6.4	68
594	Nanovector delivery of siRNA for cancer therapy. Cancer Gene Therapy, 2012, 19, 367-373.	4.6	156
595	Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 771-781.	3.4	28
596	Functional drug–gene interactions in lung cancer. Expert Review of Molecular Diagnostics, 2012, 12, 291-302.	3.1	7
597	Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Biomedicine and Pharmacotherapy, 2012, 66, 384-389.	5.6	30
598	Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. Cancer Epidemiology, 2012, 36, 341-346.	1.9	8
599	Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Critical Reviews in Oncology/Hematology, 2012, 83, 407-421.	4.4	151
600	Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. Lung Cancer, 2012, 75, 30-37.	2.0	61
601	Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer. Lung Cancer, 2012, 77, 252-259.	2.0	35
602	Molecular aspects of thymic carcinoma. Lung Cancer, 2012, 78, 127-132.	2.0	21
603	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Molecular Oncology, 2012, 6, 15-26.	4.6	66
604	Cytopathology of lung cancer: moving from morphology to molecular. Diagnostic Histopathology, 2012, 18, 313-320.	0.4	6
605	Update on lung cancer from the annual meeting of the American Society of Clinical Oncology 2012. Memo - Magazine of European Medical Oncology, 2012, 5, 253-258.	0.5	0
606	EMP-1 promotes tumorigenesis of NSCLC through PI3K/AKT pathway. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 834-838.	1.0	26
607	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nature Medicine, 2012, 18, 382-384.	30.7	782
608	Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. Journal of Medicinal Chemistry, 2012, 55, 2251-2264.	6.4	53
609	Tyrosine Kinase Inhibitors in Lung Cancer. Hematology/Oncology Clinics of North America, 2012, 26, 589-605.	2.2	32
610	Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): An Accurate and Cost-Effective Assay to Diagnose and Quantify KRAS and BRAF Mutation. PLoS ONE, 2012, 7, e36084.	2.5	55

#	Article	IF	CITATIONS
611	Anti-Proliferative Effect of Cytohesin Inhibition in Gefitinib-Resistant Lung Cancer Cells. PLoS ONE, 2012, 7, e41179.	2.5	29
612	Non-small cell lung cancer: the era of targeted therapy. Lung Cancer: Targets and Therapy, 2012, 3, 31.	2.7	8
613	Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations. Frontiers in Oncology, 2012, 2, 12.	2.8	46
614	The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease. , 2012, , .		2
615	Improving the limit of detection for Sanger sequencing: A comparison of methodologies for <i>KRAS</i> variant detection. BioTechniques, 2012, 53, 182-188.	1.8	41
616	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
617	Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Wspolczesna Onkologia, 2012, 5, 401-406.	1.4	5
618	K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. , 2012, 2012, 1-8.		23
619	Cetuximab and biomarkers in non-small-cell lung carcinoma. Biologics: Targets and Therapy, 2012, 6, 221.	3.2	10
620	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	5.5	215
621	Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature, 2012, 489, 155-159.	27.8	320
622	Foxm1 Mediates Cross Talk between Kras/Mitogen-Activated Protein Kinase and Canonical Wnt Pathways during Development of Respiratory Epithelium. Molecular and Cellular Biology, 2012, 32, 3838-3850.	2.3	59
623	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i> . Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2127-33.	7.1	410
624	Respiratory cytology in the era of molecular diagnostics: A review. Diagnostic Cytopathology, 2012, 40, 556-563.	1.0	10
625	Cooperative, Nanoparticleâ€Enabled Thermal Therapy of Breast Cancer. Advanced Healthcare Materials, 2012, 1, 84-89.	7.6	85
626	Driver mutations determine survival in smokers and neverâ€smokers with stage IIIB/IV lung adenocarcinomas. Cancer, 2012, 118, 5840-5847.	4.1	55
627	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature, 2012, 486, 537-540.	27.8	1,506
628	Pharmacogenetics of <i>EGFR</i> in lung cancer: perspectives and clinical applications. Pharmacogenomics, 2012, 13, 789-802.	1.3	38

#	Article	IF	CITATIONS
629	Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Lung Cancer, 2012, 13, 267-279.	2.6	21
630	The Value of Biomarkers in Patients With Sarcomatoid Carcinoma of the Lung: Molecular Analysis of 33 Cases. Clinical Lung Cancer, 2012, 13, 288-296.	2.6	45
631	Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. International Journal of Clinical Practice, 2012, 66, 748-752.	1.7	19
632	Distinct clinical features and outcomes in neverâ€smokers with nonsmall cell lung cancer who harbor <i>EGFR</i> or <i>KRAS</i> mutations or <i>ALK</i> rearrangement. Cancer, 2012, 118, 729-739.	4.1	132
633	Oncogenic KRASâ€induced interleukinâ€8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of nonâ€small cell lung cancer. International Journal of Cancer, 2012, 130, 1733-1744.	5.1	80
634	Thymoma and thymic carcinoma. General Thoracic and Cardiovascular Surgery, 2012, 60, 1-12.	0.9	73
635	Association of <i>KRAS</i> and <i>EGFR</i> mutations with survival in patients with advanced lung adenocarcinomas. Cancer, 2013, 119, 356-362.	4.1	143
636	Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials, 2013, 34, 8690-8707.	11.4	408
637	Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 409-419.	2.8	33
638	Modeling NSCLC Progression: Recent Advances and Opportunities Available. AAPS Journal, 2013, 15, 542-550.	4.4	12
639	MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Molecular Oncology, 2013, 7, 112-120.	4.6	70
640	Oncogenic driver mutations in lung cancer. Translational Respiratory Medicine, 2013, 1, 6.	3.8	49
641	Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology. Journal of Molecular Diagnostics, 2013, 15, 819-826.	2.8	49
642	Response to First-Line Chemotherapy in Patients With Non–Small-Cell Lung Cancer According to Epidermal Growth Factor Receptor and K-RAS Mutation Status. Clinical Lung Cancer, 2013, 14, 680-687.	2.6	19
643	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer, 2013, 80, 120-130.	2.0	43
644	The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature Medicine, 2013, 19, 1389-1400.	30.7	883
645	Management strategy of pulmonary nodule in 2013. Diagnostic and Interventional Imaging, 2013, 94, 1081-1094.	3.2	39
646	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 2013, 503, 548-551.	27.8	1,713
#	Article	IF	CITATIONS
-----	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----	-----------
647	<i>ALK</i> Rearrangements Are Mutually Exclusive with Mutations in <i>EGFR</i> or <i>KRAS</i> : An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 4273-4281.	7.0	521
648	Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation. Investigational New Drugs, 2013, 31, 1458-1465.	2.6	25
649	EGFR and HER2 inhibition in pancreatic cancer. Investigational New Drugs, 2013, 31, 558-566.	2.6	28
650	Tumor Dormancy, Oncogene Addiction, Cellular Senescence, and Self-Renewal Programs. Advances in Experimental Medicine and Biology, 2013, 734, 91-107.	1.6	36
651	Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene, 2013, 32, 4034-4042.	5.9	59
652	Clinical Genome Sequencing. , 2013, , 102-122.		29
653	Molecular Pathology of Lung Cancer. , 2013, , 443-459.		0
654	<i>KRAS</i> Mutation: Should We Test for It, and Does It Matter?. Journal of Clinical Oncology, 2013, 31, 1112-1121.	1.6	219
655	Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. Cancer Genetics, 2013, 206, 330-339.	0.4	16
656	The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Non–Small-Cell Lung Cancer: Focus on Clinical Trial Results. Clinical Lung Cancer, 2013, 14, 311-321.	2.6	11
657	Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. Journal of Clinical Oncology, 2013, 31, 3987-3996.	1.6	299
658	The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Human Pathology, 2013, 44, 2768-2773.	2.0	81
659	Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. Human Pathology, 2013, 44, 1286-1292.	2.0	19
660	Prise en charge du nodule pulmonaire en 2013. Diagnostic and Interventional Imaging, 2013, 94, 1084-1098.	0.0	0
661	A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2013, 79, 270-275.	2.0	17
662	The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. Seminars in Diagnostic Pathology, 2013, 30, 298-312.	1.5	13
663	Simultaneous suppression of Src and signal transducer and activator of transcription 3 inhibits the growth of epithelial ovarian cancer cells. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 169, 75-79.	1.1	2
664	Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 264-270.	2.5	26

#	Article	IF	CITATIONS
665	Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?. Medical Oncology, 2013, 30, 328.	2.5	33
666	Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology, 2013, 31, 1405-1414.	1.6	188
667	Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E364-E369.	3.6	213
668	Targeting Mutant KRAS for Anticancer Therapeutics: A Review of Novel Small Molecule Modulators. Journal of Medicinal Chemistry, 2013, 56, 5219-5230.	6.4	104
669	Inhibition of the <scp>PI</scp> 3K/ <scp>AKT</scp> pathway potentiates cytotoxicity of <scp>EGFR</scp> kinase inhibitors in tripleâ€negative breast cancer cells. Journal of Cellular and Molecular Medicine, 2013, 17, 648-656.	3.6	67
670	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multiâ€targeted kinase inhibitors in pimasertibâ€resistant human lung and colorectal cancer cells. International Journal of Cancer, 2013, 133, 2089-2101.	5.1	81
671	Identification of driver mutations in lung cancer: first step in personalized cancer. Targeted Oncology, 2013, 8, 3-14.	3.6	26
672	Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nature Reviews Rheumatology, 2013, 9, 267-276.	8.0	86
673	Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. Cellular Oncology (Dordrecht), 2013, 36, 277-288.	4.4	80
674	Complications of Targeted Drug Therapies for Solid Malignancies: Manifestations and Mechanisms. American Journal of Roentgenology, 2013, 200, 475-483.	2.2	33
675	Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. Pharmacogenomics and Personalized Medicine, 2013, 6, 25.	0.7	30
676	KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy. Annals of Surgical Oncology, 2013, 20, 1381-1388.	1.5	73
677	Research progress in the use of combinations of platinum-based chemotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors. Chinese-German Journal of Clinical Oncology, 2013, 12, 133-136.	0.1	0
678	From human genome to cancer genome: The first decade. Genome Research, 2013, 23, 1054-1062.	5.5	132
679	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832.	1.9	24
680	Advances in personalized therapy for lung cancer. Expert Opinion on Medical Diagnostics, 2013, 7, 475-485.	1.6	9
681	Collections of Simultaneously Altered Genes as Biomarkers of Cancer Cell Drug Response. Cancer Research, 2013, 73, 1699-1708.	0.9	46
682	The Genetic Landscape of Pheochromocytomas and Paragangliomas: Somatic Mutations Take Center Stage. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2679-2681.	3.6	18

#	Article	IF	CITATIONS
683	<i>KRAS</i> mutant tumor subpopulations can subvert durable responses to personalized cancer treatments. Personalized Medicine, 2013, 10, 191-199.	1.5	19
684	Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncology Letters, 2013, 6, 1207-1212.	1.8	23
685	Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays (Basel, Switzerland), 2013, 2, 318-339.	1.4	14
686	Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers. Seminars in Interventional Radiology, 2013, 30, 191-198.	0.8	67
687	Molecular Markers for Novel Therapeutic Strategies in Pancreatic Endocrine Tumors. Pancreas, 2013, 42, 411-421.	1.1	38
688	Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. Cancer Journal (Sudbury, Mass), 2013, 19, 263-271.	2.0	4
689	Data Set for Reporting of Lung Carcinomas: Recommendations From International Collaboration on Cancer Reporting. Archives of Pathology and Laboratory Medicine, 2013, 137, 1054-1062.	2.5	23
690	Analysis of <i>EGFR</i> , <i>EML4-ALK</i> , <i>KRAS</i> , and <i>c-MET</i> mutations in Chinese lung adenocarcinoma patients. Experimental Lung Research, 2013, 39, 328-335.	1.2	53
691	Enhanced antitumor activity of erlotinib in combination with the <scp>H</scp> sp90 inhibitor <scp>CH</scp> 5164840 against nonâ€smallâ€cell lung cancer. Cancer Science, 2013, 104, 1346-1352.	3.9	33
692	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews, 2013, 65, 1351-1395.	16.0	33
693	The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death and Disease, 2013, 4, e810-e810.	6.3	67
694	Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells. Cell Death and Disease, 2013, 4, e814-e814.	6.3	56
695	From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development. Journal of the National Cancer Institute, 2013, 105, 1441-1456.	6.3	51
696	Resistance to EGFR-TKI Can Be Mediated through Multiple Signaling Pathways Converging upon Cap-Dependent Translation in EGFR-Wild Type NSCLC. Journal of Thoracic Oncology, 2013, 8, 1142-1147.	1.1	12
697	Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells. Journal of Thoracic Oncology, 2013, 8, 259-269.	1.1	39
698	Patterns of DNA Mutations and ALK Rearrangement in Resected Node Negative Lung Adenocarcinoma. Journal of Thoracic Oncology, 2013, 8, 408-414.	1.1	38
699	MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases. Journal of Thoracic Oncology, 2013, 8, 574-581.	1.1	49
700	Gefitinib: re-emerging from the shadows. Lung Cancer Management, 2013, 2, 423-437.	1.5	0

#	Article	IF	CITATIONS
701	Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients. Experimental and Therapeutic Medicine, 2013, 5, 495-498.	1.8	13
702	Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. Oncology Letters, 2013, 5, 68-72.	1.8	5
703	Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. Oncology Letters, 2013, 5, 440-446.	1.8	14
704	Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. Oncology Reports, 2013, 30, 1045-1052.	2.6	30
705	The genetics and biology of KRAS in lung cancer. Chinese Journal of Cancer, 2013, 32, 63-70.	4.9	76
706	The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences inKRASMutations in Korean Patients with Lung Adenocarcinoma. Yonsei Medical Journal, 2013, 54, 865.	2.2	18
707	Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e51021.	2.5	7
708	Identifying Resistance Mechanisms against Five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines. PLoS ONE, 2013, 8, e59503.	2.5	21
709	Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis. PLoS ONE, 2013, 8, e69604.	2.5	94
710	Common and Rare EGFR and KRAS Mutations in a Dutch Non-Small-Cell Lung Cancer Population and Their Clinical Outcome. PLoS ONE, 2013, 8, e70346.	2.5	32
711	Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors. Tuberculosis and Respiratory Diseases, 2013, 75, 188.	1.8	10
712	Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy. Frontiers in Pharmacology, 2013, 4, 58.	3.5	12
713	Identification of candidate genes for lung cancer somatic mutation test kits. Genetics and Molecular Biology, 2013, 36, 455-464.	1.3	19
714	Biomarkers in Lung Cancer: Integration with Radiogenomics Data. , 2013, , .		1
715	Adenocarcinoma of the lung. , 2013, , 1043-1092.		1
716	Transcriptome-Wide Analysis of UTRs in Non-Small Cell Lung Cancer Reveals Cancer-Related Genes with SNV-Induced Changes on RNA Secondary Structure and miRNA Target Sites. PLoS ONE, 2014, 9, e82699.	2.5	30
717	In-Depth Analysis Shows Synergy between Erlotinib and miR-34a. PLoS ONE, 2014, 9, e89105.	2.5	62
718	Cancer <i>In Silico</i> Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes. Molecular Cancer Therapeutics, 2014, 13, 3230-3240.	4.1	21

#	Article	IF	CITATIONS
719	EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. Annals of Oncology, 2014, 25, 1941-1948.	1.2	20
720	Oncogenic RIT1 mutations in lung adenocarcinoma. Oncogene, 2014, 33, 4418-4423.	5.9	72
721	Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients withEGFRwild-type tumors. Lung Cancer Management, 2014, 3, 101-116.	1.5	0
722	Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. British Journal of Cancer, 2014, 111, 2203-2204.	6.4	37
723	Thoracic Neoplasia: Carcinoma. , 2014, , 2677-2689.		0
724	Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models. Frontiers in Oncology, 2014, 4, 344.	2.8	15
725	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Non–Small Cell Carcinoma of the Lung. Archives of Pathology and Laboratory Medicine, 2014, 138, 171-174.	2.5	20
726	Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma. Clinical Cancer Research, 2014, 20, 1020-1028.	7.0	128
727	Nullifying the <i>CDKN2AB</i> Locus Promotes Mutant K-ras Lung Tumorigenesis. Molecular Cancer Research, 2014, 12, 912-923.	3.4	39
728	COPD-related adenocarcinoma presents low aggressiveness morphological and molecular features compared to smoker tumours. Lung Cancer, 2014, 86, 311-317.	2.0	15
729	A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization. Advances in Experimental Medicine and Biology, 2014, 799, 85-117.	1.6	98
730	Oncogenic Ras/ERK Signaling Activates CDCP1 to Promote Tumor Invasion and Metastasis. Molecular Cancer Research, 2014, 12, 1449-1459.	3.4	61
731	Stable and Efficient Transfection of siRNA for Mutated KRAS Silencing Using Novel Hybrid Nanoparticles. Molecular Pharmaceutics, 2014, 11, 4415-4424.	4.6	22
732	Factors associated with early progression of nonâ€smallâ€cell lung cancer treated by epidermal growth factor receptor tyrosineâ€kinase inhibitors. Cancer Medicine, 2014, 3, 61-69.	2.8	6
733	Correlation of Cytomorphology and Molecular Findings in EGFR+, KRAS+, and ALK+ Lung Carcinomas. American Journal of Clinical Pathology, 2014, 141, 420-428.	0.7	21
734	The PI3K/AKT pathway promotes gefitinib resistance in mutant <i>KRAS</i> lung adenocarcinoma by a deacetylaseâ€dependent mechanism. International Journal of Cancer, 2014, 134, 2560-2571.	5.1	50
735	Antiâ€ŧumor activity of <scp>WK</scp> 88â€1, a novel geldanamycin derivative, in gefitinibâ€resistant nonâ€small cell lung cancers with Met amplification. Cancer Science, 2014, 105, 1245-1253.	3.9	22
736	Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas. BMC Cancer, 2014, 14, 982.	2.6	27

#	Article	IF	CITATIONS
737	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models. Journal of Experimental and Clinical Cancer Research, 2014, 33, 52.	8.6	43
738	ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biology and Therapy, 2014, 15, 317-328.	3.4	48
739	Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. Journal of Thoracic Oncology, 2014, 9, 1523-1531.	1.1	19
740	Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. Genetical Research, 2014, 96, e002.	0.9	16
741	<i>KRAS</i> Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing. Korean Journal of Pathology, 2014, 48, 100.	1.3	20
742	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1118-1127.	3.7	131
743	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts. British Journal of Cancer, 2014, 110, 2812-2820.	6.4	200
744	Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer. Experimental Cell Research, 2014, 322, 168-177.	2.6	43
745	Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma. In Vitro Cellular and Developmental Biology - Animal, 2014, 50, 519-526.	1.5	3
746	Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and corresponding liver metastases. International Journal of Clinical Oncology, 2014, 19, 113-120.	2.2	16
747	Reduced <i>NF1</i> Expression Confers Resistance to EGFR Inhibition in Lung Cancer. Cancer Discovery, 2014, 4, 606-619.	9.4	183
748	Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer. Clinical Cancer Research, 2014, 20, 1428-1444.	7.0	81
749	Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing. American Journal of Clinical Pathology, 2014, 141, 856-866.	0.7	128
750	Update: The Status of Clinical Trials With Kinase Inhibitors in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1543-1555.	3.6	30
751	Molecular analysis of circulating tumour cells—biology and biomarkers. Nature Reviews Clinical Oncology, 2014, 11, 129-144.	27.6	535
752	Genomic Sequencing for Cancer Diagnosis and Therapy. Annual Review of Medicine, 2014, 65, 33-48.	12.2	35
753	Noninvasive Detection of Response and Resistance in <i>EGFR</i> Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA. Clinical Cancer Research, 2014, 20, 1698-1705.	7.0	717
754	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	8.7	255

	Сітат	ION REPORT	
#	Article	IF	Citations
755	HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head and Neck, 2014, 36, 1547-1554.	2.0	31
756	Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology. Journal of Molecular Diagnostics, 2014, 16, 89-105.	2.8	168
757	The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Modern Pathology, 2014, 27, 690-700.	5.5	121
758	Aspects biologiques des cancers bronchiques. Revue Des Maladies Respiratoires Actualites, 2014, 6, 311-319.	0.0	0
759	Carcinome bronchique non à petites cellules : quelle chimiothérapie de rattrapage ?. Revue Des Maladies Respiratoires Actualites, 2014, 6, 442-452.	0.0	0
760	High frequency of <scp>BRAF</scp> <scp>V600E</scp> mutations in ameloblastoma. Journal of Pathology, 2014, 232, 492-498.	4.5	240
761	Fluorescence Detection of <i>KRAS2</i> mRNA Hybridization in Lung Cancer Cells with PNA-Peptides Containing an Internal Thiazole Orange. Bioconjugate Chemistry, 2014, 25, 1697-1708.	3.6	32
762	Unique volatolomic signatures of TP53 and KRAS in lung cells. British Journal of Cancer, 2014, 111, 1213-1221.	6.4	43
763	Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Toxicology Reports, 2014, 1, 309-318.	3.3	64
764	ERÎ ² Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling. Molecular Cancer Research, 2014, 12, 843-854.	3.4	14
765	Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2058-2065.	6.4	75
766	Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory Investigation, 2014, 94, 129-137.	3.7	188
767	Customized Adjuvant Phase II Trial in Patients With Non–Small-Cell Lung Cancer: IFCT-0801 TASTE. Journal of Clinical Oncology, 2014, 32, 1256-1261.	1.6	66
768	Cationic Lipid-Assisted Polymeric Nanoparticle Mediated GATA2 siRNA Delivery for Synthetic Lethal Therapy of KRAS Mutant Non-Small-Cell Lung Carcinoma. Molecular Pharmaceutics, 2014, 11, 2612-2622	2. 4.6	30
769	Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE). Lung Cancer, 2014, 86, 54-58.	2.0	3
770	The end of KRAS, and other, cancers? A new way forward. Drug Discovery Today, 2014, 19, 383-387.	6.4	5
771	Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean <i>inÂsilico</i> model. Molecular Oncology, 2014, 8, 351-365.	4.6	74
772	Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer, 2014, 83, 374-382.	2.0	40

#	Article	IF	CITATIONS
773	The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non–small cell lung cancer. Human Pathology, 2014, 45, 926-934.	2.0	51
774	Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrierâ€Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor. Advanced Functional Materials, 2014, 24, 5482-5492.	14.9	17
775	Genes and Pathology of Non-Small Cell Lung Carcinoma. Seminars in Oncology, 2014, 41, 28-39.	2.2	59
777	Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR. Oncology Reports, 2014, 31, 2619-2624.	2.6	12
778	Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells. Molecular Medicine Reports, 2014, 9, 2417-2422.	2.4	14
779	Tumor <scp>MET</scp> expression profile predicts the outcome of nonâ€small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Thoracic Cancer, 2014, 5, 517-524.	1.9	5
780	The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2015, 10, 903-909.	1.1	36
781	Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2015, 10, 1156-1162.	1.1	137
782	Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. Oncology Letters, 2015, 10, 2176-2184.	1.8	26
783	Epidermal growth factor receptor variant <scp>III</scp> mutation in <scp>C</scp> hinese patients with squamous cell cancer of the lung. Thoracic Cancer, 2015, 6, 319-326.	1.9	10
784	Kinetic Hairpin Oligonucleotide Blockers for Selective Amplification of Rare Mutations. Scientific Reports, 2015, 4, 5921.	3.3	9
785	L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report. Oncology Letters, 2015, 10, 1293-1296.	1.8	7
786	Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. Cancer Informatics, 2015, 14, CIN.S22941.	1.9	16
787	Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncology Letters, 2015, 10, 1775-1782.	1.8	27
788	Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation. Journal of Hematology and Oncology, 2015, 8, 127.	17.0	45
789	Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma. Cancer Control, 2015, 22, 193-199.	1.8	23
790	Selective Targeting of the KRAS Codonâ€12 Mutation Sequence by Pyrrole–Imidazole Polyamide <i>seco</i> BI Conjugates. Chemistry - A European Journal, 2015, 21, 14996-15003.	3.3	17
791	FDG Uptake in Non–Small Cell Lung Cancer Is Not an Independent Predictor of EGFR or KRAS Mutation Status. Clinical Nuclear Medicine, 2015, 40, 950-958.	1.3	47

		CITATION REPORT	
#	Article	IF	CITATIONS
793	Role of network biology and network medicine in early detection of cancer. , 0, , 457-463.		0
794	The distinctive nature of adenocarcinoma of the lung. OncoTargets and Therapy, 2015, 8, 2399.	2.0	16
795	The impact of erlotinib use in non-small-cell lung cancer patients treated in a private reference general hospital and in a private cancer clinic from 2005 to 2011. Einstein (Sao Paulo, Brazil), 2015, 13, 215-220.	0.7	2
796	Roles of NOTCH1 as a Therapeutic Target and a Biomarker for Lung Cancer: Controversies and Perspectives. Disease Markers, 2015, 2015, 1-8.	1.3	27
797	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget, 2015, 6, 18162-18173.	1.8	90
798	Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity. Oncotarget, 2015, 6, 18224-18237.	1.8	71
799	Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. Revista Portuguesa De Pneumologia, 2015, 21, 113-125.	0.7	3
800	Amplification of Chromosome 8 Genes in Lung Cancer. Journal of Cancer, 2015, 6, 270-275.	2.5	34
801	Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1427-1439.	2.5	12
802	Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers. Scientific Reports, 2015, 5, 9755.	3.3	43
803	Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas. Nature Communications, 2015, 6, 10131.	12.8	93
804	Integrating RAS Status into Prognostic Signatures for Adenocarcinomas of the Lung. Clinical Cancer Research, 2015, 21, 1477-1486.	7.0	13
805	EGFR and K-RAS mutations and ERCC1, TUBB3, TYMS, RRM1 and EGFR mRNA expression in non-small cell lung cancer: Correlation with clinical response to gefitinib or chemotherapy. Molecular and Clinical Oncology, 2015, 3, 1123-1128.	1.0	4
806	Clinical potential of gene mutations in lung cancer. Clinical and Translational Medicine, 2015, 4, 33.	4.0	36
807	Survival in ampullary cancer: Potential role of different KRAS mutations. Surgery, 2015, 157, 260-268.	1.9	36
808	Diet-Induced Unresolved ER Stress Hinders KRAS-Driven Lung Tumorigenesis. Cell Metabolism, 2015, 21, 117-125.	16.2	35
809	Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients. Pathology and Oncology Research, 2015, 21, 675-687.	1.9	11
810	Combinatorial Action of MicroRNAs <i>let-7</i> and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle, 2015, 14, 2171-2180.	2.6	131

#	Article	IF	CITATIONS
811	Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction. Tumor Biology, 2015, 36, 2993-2999.	1.8	7
812	Molecular histology of lung cancer: From targets to treatments. Cancer Treatment Reviews, 2015, 41, 361-375.	7.7	142
813	Exome sequencing identifies frequent mutation of MLL2 in non–small cell lung carcinoma from Chinese patients. Scientific Reports, 2014, 4, 6036.	3.3	33
814	Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B, 2015, 5, 390-401.	12.0	383
815	Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK. Cancers, 2015, 7, 930-949.	3.7	83
816	Peripheral Lung Adenocarcinomas With KRAS Mutations Are More Likely to Invade Visceral Pleura. Archives of Pathology and Laboratory Medicine, 2015, 139, 189-193.	2.5	11
817	Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts. Phytomedicine, 2015, 22, 560-567.	5.3	32
818	MET: a new promising biomarker in non-small-cell lung carcinoma. Pharmacogenomics, 2015, 16, 631-647.	1.3	21
819	The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. Tumor Biology, 2015, 36, 6417-6424.	1.8	15
820	Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization. Molecular Cancer, 2015, 14, 4.	19.2	60
821	May CTC technologies promote better cancer management?. EPMA Journal, 2015, 6, 1.	6.1	31
822	Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond. Chinese Journal of Cancer, 2015, 34, 149-60.	4.9	20
823	Application of biomarkers in oncology clinical trials. Clinical Investigation, 2015, 5, 61-74.	0.0	1
824	How fisetin reduces the impact of age and disease on CNS function. Frontiers in Bioscience - Scholar, 2015, 7, 58-82.	2.1	7
825	Differences in the survival of patients with recurrent versus de novo metastatic <i>KRAS</i> â€mutant and <i>EGFR</i> â€mutant lung adenocarcinomas. Cancer, 2015, 121, 2078-2082.	4.1	15
827	Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas. Journal of Thoracic Oncology, 2015, 10, 431-437.	1.1	98
828	KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non–Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 33-40.	1.3	39
829	Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Anti-Cancer Drugs, 2015, 26, 371-378.	1.4	10

#	Article	IF	CITATIONS
830	MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. Pharmacological Research, 2015, 102, 90-106.	7.1	4
831	Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer, 2015, 15, 32.	2.6	34
832	WT1 Enhances Proliferation and Impedes Apoptosis in KRAS Mutant NSCLC via Targeting cMyc. Cellular Physiology and Biochemistry, 2015, 35, 647-662.	1.6	16
833	Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. Lung Cancer, 2015, 90, 534-541.	2.0	43
834	The impact of the Cancer Genome Atlas on lung cancer. Translational Research, 2015, 166, 568-585.	5.0	83
835	CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR-Targeted Therapy for Colorectal Cancer—From Concept to Practice. Clinical Cancer Research, 2015, 21, 3578-3580.	7.0	17
836	Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. Nature Communications, 2015, 6, 8154.	12.8	39
837	PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics, 2015, 16, 1843-1862.	1.3	180
838	Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 192-197.	2.2	20
839	Regulatory crosstalk between lineage-survival oncogenes <i>KLF5, GATA4</i> and <i>GATA6</i> cooperatively promotes gastric cancer development. Gut, 2015, 64, 707-719.	12.1	148
839 840	Regulatory crosstalk between lineage-survival oncogenes <i>KLF5, GATA4</i> and <i>GATA6</i> cooperatively promotes gastric cancer development. Gut, 2015, 64, 707-719. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015, 29, 27-37.	12.1 7.2	148 51
839 840 841	Regulatory crosstalk between lineage-survival oncogenes <i>KLF5, GATA4</i> and<i>GATA6</i> cooperatively promotes gastric cancer development. Gut, 2015, 64, 707-719. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015, 29, 27-37. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. Mini-Reviews in Medicinal Chemistry, 2016, 16, 391-403.	12.1 7.2 2.4	148 51 45
839 840 841 842	Regulatory crosstalk between lineage-survival oncogenes <i>KLF5, GATA4</i> GATA4 GATA4 <	12.1 7.2 2.4 1.0	148 51 45 36
839 840 841 842 842	Regulatory crosstalk between lineage-survival oncogenes <i>KLF5, GATA4 </i> and <i>GATA6 </i> cooperatively promotes gastric cancer development. Gut, 2015, 64, 707-719. Identification of Weel as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015, 29, 27-37. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. Mini-Reviews in Medicinal Chemistry, 2016, 16, 391-403. Adequacy of endobronchial ultrasound-guided transbronchial needle aspiration samples processed as histopathological samples for genetic mutation analysis in lung adenocarcinoma. Molecular and Clinical Oncology, 2016, 4, 119-125. Detection of <i>ECFR</i> and <i>KRAS</i> Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer. Journal of Korean Medical Science, 2016, 31, 1224.	12.1 7.2 2.4 1.0 2.5	148 51 45 36 9
839 840 841 842 843 843	Regulatory crosstalk between lineage-survival oncogenes <i>KLF5, GATA4</i> and <i>GATA6</i> cooperatively promotes gastric cancer development. Gut, 2015, 64, 707-719. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015, 29, 27-37. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. Mini-Reviews in Medicinal Chemistry, 2016, 16, 391-403. Adequacy of endobronchial ultrasound-guided transbronchial needle aspiration samples processed as histopathological samples for genetic mutation analysis in lung adenocarcinoma. Molecular and Clinical Oncology, 2016, 4, 119-125. Detection of <i>EGFR</i> and <i>KRAS</i> Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer. Journal of Korean Medical Science, 2016, 31, 1224. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget, 2016, 7, 61755-61763.	12.1 7.2 2.4 1.0 2.5 1.8	148 51 45 36 9
839 840 841 842 843 843 844	Regulatory crosstalk between lineage-survival oncogenes (i) KLF5, GATA4 and (i) CATA6 cooperatively promotes gastric cancer development. Gut, 2015, 64, 707-719. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015, 29, 27-37. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. Mini-Reviews in Medicinal Chemistry, 2016, 16, 391-403. Adequacy of endobronchial ultrasound-guided transbronchial needle aspiration samples processed as histopathological samples for genetic mutation analysis in lung adenocarcinoma. Molecular and Clinical Oncology, 2016, 4, 119-125. Detection of <>>EGFR Detection of <>>EGFR Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget, 2016, 7, 61755-61763. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. OncoTargets and Therapy, 2016, 9, 833.	12.1 7.2 2.4 1.0 2.5 1.8 2.0	148 51 45 36 9 29 38
 839 840 841 842 843 844 844 845 846 	Regulatory crosstalk between lineage-survival oncogenes ()>KLFS, GATA4 GATA4 GATA4 CATA6 COPERATION CONCERNENT CONCERNENT Coperatively promotes gastric cancer development. Gut, 2015, 64, 707-719. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. Leukemia, 2015, 29, 27-37. Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target. Mini-Reviews in Medicinal Chemistry, 2016, 16, 391-403. Adequacy of endobronchial ultrasound-guided transbronchial needle aspiration samples processed as histopathological samples for genetic mutation analysis in lung adenocarcinoma. Molecular and Clinical Oncology, 2016, 4, 119-125. Detection of <i>ECFR</i> And <i>KRAS</i> Mutational profiling of non-small-cell lung cancer patients resistant to first-generation ECFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget, 2016, 7, 61755-61763. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. OncoTargets and Therapy, 2016, 9, 833. Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. OncoTargets and Therapy, 2016, Volume 9, 6843-6855.	12.1 7.2 2.4 1.0 2.5 1.8 2.0 2.0	148 51 45 36 9 29 29 38 30

#	Article	IF	CITATIONS
848	Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations. Wspolczesna Onkologia, 2016, 1, 33-38.	1.4	8
849	Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis. International Journal of Molecular Sciences, 2016, 17, 524.	4.1	28
850	Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer. Journal of Personalized Medicine, 2016, 6, 3.	2.5	9
851	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0147344.	2.5	81
852	Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing. PLoS ONE, 2016, 11, e0152851.	2.5	9
853	Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19â€ [−] 784 Diverse Solid Tumors. JAMA Oncology, 2016, 2, 1565.	7.1	195
854	Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells. Pancreas, 2016, 45, 269-280.	1.1	7
855	HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib. Oncology Letters, 2016, 12, 5363-5369.	1.8	3
856	Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC. Scientific Reports, 2016, 6, 33860.	3.3	189
857	Epidemiology of driver mutations in lung cancer in a German tertiary hospital in patients with testing indication. Personalized Medicine, 2016, 13, 315-323.	1.5	3
859	Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochemical and Biophysical Research Communications, 2016, 474, 154-160.	2.1	92
860	Exome Sequencing and the Management of Neurometabolic Disorders. New England Journal of Medicine, 2016, 374, 2246-2255.	27.0	254
861	Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value. Clinical Lung Cancer, 2016, 17, 271-278.	2.6	17
862	Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e449-e452.	1.9	22
863	Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement. , 2016, 165, 79-92.		60
864	Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Review of Molecular Diagnostics, 2016, 16, 737-749.	3.1	24
865	Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clinical Cancer Research, 2016, 22, 5772-5782.	7.0	279
866	Clinical approach of intratumoral heterogeneity in lung adenocarcinoma. Two clinical cases with changing somatic driver mutations. Cancer Treatment and Research Communications, 2016, 9, 96-99.	1.7	0

#	Article	IF	CITATIONS
867	Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nature Reviews Drug Discovery, 2016, 15, 771-785.	46.4	457
868	Diagnosis and Molecular Classification of Lung Cancer. Cancer Treatment and Research, 2016, 170, 25-46.	0.5	172
869	Intrinsic K-Ras dynamics: A novel molecular dynamics data analysis method shows causality between residue pair motions. Scientific Reports, 2016, 6, 37012.	3.3	26
870	A genetic cell context-dependent role for ZEB1 in lung cancer. Nature Communications, 2016, 7, 12231.	12.8	54
871	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nature Communications, 2016, 7, 11815.	12.8	520
872	Contribution of18Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma. Cancer Biomarkers, 2016, 16, 489-498.	1.7	16
873	Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomarkers in Cancer, 2016, 8s1, BIC.S34414.	3.6	44
874	Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations. Journal of the American Society of Cytopathology, 2016, 5, 123-132.	0.5	18
875	Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth. Cancer Cell International, 2016, 16, 9.	4.1	68
876	Hybridization-Induced Aggregation Technology for Practical Clinical Testing. Journal of Molecular Diagnostics, 2016, 18, 546-553.	2.8	2
877	Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease. Physiological Reviews, 2016, 96, 1025-1069.	28.8	166
878	A primer on precision medicine informatics. Briefings in Bioinformatics, 2016, 17, 145-153.	6.5	40
879	Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancerâ~†. Lung Cancer, 2016, 92, 29-34.	2.0	44
880	Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Annals of Oncology, 2016, 27, 693-699.	1.2	73
881	Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays. Molecular and Cellular Proteomics, 2016, 15, 682-691.	3.8	39
882	Spectrum of <i>EGFR</i> gene mutations in Vietnamese patients with non–small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 86-90.	1.1	10
883	Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance. Cancer Chemotherapy and Pharmacology, 2016, 77, 583-593.	2.3	30
884	Fine-needle aspiration of small pulmonary nodules yields material for reliable molecular analysis of adenocarcinomas. Journal of the American Society of Cytopathology, 2016, 5, 57-63.	0.5	3

#	Article	IF	CITATIONS
885	Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nature Communications, 2016, 7, 10690.	12.8	418
886	Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts. Targeted Oncology, 2016, 11, 507-514.	3.6	11
887	Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. BMC Cancer, 2016, 16, 87.	2.6	20
888	MEGSA: A Powerful and Flexible Framework for Analyzing Mutual Exclusivity of Tumor Mutations. American Journal of Human Genetics, 2016, 98, 442-455.	6.2	40
889	Recent advances in the pathology and molecular genetics of lung cancer: A practical review for cytopathologists. Journal of the American Society of Cytopathology, 2016, 5, 252-265.	0.5	0
891	Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine, 2016, 10, 53-68.	2.5	56
892	<i>FGFR1</i> Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status. American Journal of Clinical Pathology, 2016, 145, 55-61.	0.7	10
893	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunology Research, 2016, 4, 204-214.	3.4	175
894	Computations underlying sensorimotor learning. Current Opinion in Neurobiology, 2016, 37, 7-11.	4.2	86
895	siRNA delivered by EGFR-specific scFv sensitizes EGFR-TKI-resistant human lung cancer cells. Biomaterials, 2016, 76, 196-207.	11.4	26
896	Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study. Tumor Biology, 2016, 37, 887-896.	1.8	10
897	Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-NaÃ⁻ve EGFR L858R-Induced Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 426-435.	7.0	46
898	Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable <i>MET</i> Gene Mutations. Journal of Clinical Oncology, 2016, 34, 794-802.	1.6	287
899	Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas. Clinical Oral Investigations, 2016, 20, 541-551.	3.0	6
900	A targetable HB-EGF–CITED4 axis controls oncogenesis in lung cancer. Oncogene, 2017, 36, 2946-2956.	5.9	19
901	The feasibility of using mutation detection in ctDNA to assess tumor dynamics. International Journal of Cancer, 2017, 140, 2642-2647.	5.1	82
902	siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer. Molecular Therapy - Nucleic Acids, 2017, 6, 259-268.	5.1	14
903	Tissue-specific tumorigenesis: context matters. Nature Reviews Cancer, 2017, 17, 239-253.	28.4	234

#	Article	IF	CITATIONS
904	Selective targeting of point-mutated KRAS through artificial microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4203-E4212.	7.1	38
905	Synthetic Route Development for the Laboratory Preparation of Eupalinilide E. Journal of Organic Chemistry, 2017, 82, 4640-4653.	3.2	11
906	KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2017, 66, 1175-1187.	4.2	211
907	Lung Cancer Biomarkers in Circulation. , 2017, , 71-108.		0
908	Lung Cancer Biomarkers. Hematology/Oncology Clinics of North America, 2017, 31, 13-29.	2.2	180
909	Lung cancer samples preserved in liquid medium: One step beyond cytology. Diagnostic Cytopathology, 2017, 45, 915-921.	1.0	1
910	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nature Communications, 2017, 8, 15617.	12.8	38
911	JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Molecular Cancer Therapeutics, 2017, 16, 1645-1657.	4.1	18
912	Drug-biomarker co-development in oncology – 20 years and counting. Drug Resistance Updates, 2017, 30, 48-62.	14.4	48
913	Clinicopathological and prognostic features of surgically resected pathological stage <scp>I</scp> lung adenocarcinoma harboring epidermal growth factor receptor and <scp>K</scp> â€ <i>ras</i> mutation. Thoracic Cancer, 2017, 8, 229-237.	1.9	6
914	Molecular biomarkers for lung adenocarcinoma. European Respiratory Journal, 2017, 49, 1601734.	6.7	110
915	Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. Scientific Reports, 2017, 7, 583.	3.3	141
916	P3.02b-105 Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Journal of Thoracic Oncology, 2017, 12, S1256-S1257.	1.1	0
917	EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathology and Oncology Research, 2017, 23, 673-677.	1.9	28
918	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. Cancer Treatment Reviews, 2017, 53, 61-69.	7.7	118
919	Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicology and Applied Pharmacology, 2017, 335, 16-27.	2.8	17
920	Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. European Journal of Medicinal Chemistry, 2017, 142, 493-505.	5.5	30
921	Inhibition of histone deacetylases sensitizes EGF receptorâ€TK inhibitorâ€resistant nonâ€smallâ€cell lung cancer cells to erlotinib <scp><i>in vitro</i></scp> and <scp><i>in vivo</i></scp> . British Journal of Pharmacology, 2017, 174, 3608-3622.	5.4	34

#	Article	IF	Citations
922	Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients. Pathology, 2017, 49, 604-610.	0.6	11
923	Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA. Journal of Molecular Diagnostics, 2017, 19, 697-710.	2.8	17
924	EGFR Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 103-116.	0.1	0
925	In vivo evidence that RBM5 is a tumour suppressor in the lung. Scientific Reports, 2017, 7, 16323.	3.3	29
926	Can <i>ad hoc</i> analyses of clinical trials help personalize treatment decisions?. British Journal of Clinical Pharmacology, 2017, 83, 2337-2338.	2.4	3
927	From academia to industry: a road more travelled. Annals of Oncology, 2017, 28, 2312-2314.	1.2	4
928	Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primaryEGFR mutation plus secondaryMET amplification and a novel acquired crizotinib-resistant mutationMET G1108C. Annals of Oncology, 2017, 28, 2622-2624.	1.2	15
929	DeSigN: connecting gene expression with therapeutics for drug repurposing and development. BMC Genomics, 2017, 18, 934.	2.8	62
930	Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients. Cancer Cell International, 2017, 17, 47.	4.1	10
931	In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene, 2017, 36, 2309-2318.	5.9	27
932	Impact of <i>TP53</i> Mutations on Outcome in <i>EGFR</i> -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2017, 23, 2195-2202.	7.0	208
933	Label-free and high-sensitive detection of Kirsten rat sarcoma viral oncogene homolog and epidermal growth factor receptor mutation using Kelvin probe force microscopy. Biosensors and Bioelectronics, 2017, 87, 222-228.	10.1	21
934	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 569-576.	5.0	131
935	K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. European Journal of Medicinal Chemistry, 2017, 125, 299-314.	5.5	39
936	Molecular Testing in Lung Cancer. , 2017, , 287-303.		2
937	Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles. Cancer Nanotechnology, 2017, 8, 7.	3.7	39
938	Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR†TKI. Oncology Letters, 2017, 15, 901-907.	1.8	13
939	Lentivirus-mediated silencing of HOTAIR IncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung adenocarcinoma. Oncology Letters, 2018, 15, 2829-2838.	1.8	23

#	Article	IF	CITATIONS
941	ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers, 2017, 9, 33.	3.7	25
942	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Frontiers in Oncology, 2017, 7, 97.	2.8	12
943	The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor. Cancer Management and Research, 2017, Volume 9, 801-811.	1.9	14
944	The resistance mechanisms and treatment strategies for <i>EGFR</i> -mutant advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 71358-71370.	1.8	51
945	Classifying cancer genome aberrations by their mutually exclusive effects on transcription. BMC Medical Genomics, 2017, 10, 66.	1.5	7
946	Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget, 2017, 8, 90557-90578.	1.8	34
947	Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. Translational Lung Cancer Research, 2017, 6, 431-443.	2.8	25
948	Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer. Journal of Controlled Release, 2018, 275, 117-128.	9.9	63
949	Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts. Oncology Letters, 2018, 15, 4676-4682.	1.8	2
950	RAS–MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i> -Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR–MEK Blockade. Molecular Cancer Therapeutics, 2018, 17, 1526-1539.	4.1	39
951	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 2018, 23, 172-180.e3.	6.4	119
952	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. Critical Reviews in Oncology/Hematology, 2018, 123, 149-161.	4.4	50
953	Targeting EGFR ^{L858R/T790M} and EGFR ^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry. Medicinal Research Reviews, 2018, 38, 1550-1581.	10.5	113
954	The biology and management of non-small cell lung cancer. Nature, 2018, 553, 446-454.	27.8	2,877
955	MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription. Tumori, 2018, 104, 221-231.	1.1	10
956	Cost-effectiveness of <i>KRAS</i> , <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. European Respiratory Journal, 2018, 51, 1701467.	6.7	16
957	Predictive approaches for drug combination discovery in cancer. Briefings in Bioinformatics, 2018, 19, 263-276.	6.5	75
958	The somatic mutation landscape of premalignant colorectal adenoma. Gut, 2018, 67, 1299-1305.	12.1	52

#	Article	IF	CITATIONS
959	Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives. Medicinal Chemistry Research, 2018, 27, 161-170.	2.4	7
960	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 334-340.	7.0	323
961	Clinical Presentation and Prognostic Factors in Lung Cancer. , 2018, , 186-198.e6.		0
962	Molecular Testing in Lung Cancer. , 2018, , 164-177.e5.		0
963	The Use of a Novel Immunohistochemical Triple Cocktail in the Subclassification of Resected Non–Small Cell Lung Carcinomas: A Comparative Study With Morphology and Traditional Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 27-34.	1.2	2
964	Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in <i>KRAS</i> -mutant non-small cell lung cancer. Oncotarget, 2018, 9, 31572-31589.	1.8	42
965	A REVIEW: STATUS OF GENETIC MODULATED NONSMALL CELL LUNG CANCER TARGETS AND TREATMENT (CURRENT UPDATES IN DRUGS FOR NON-SMALL CELL LUNG CANCER TREATMENT). Asian Journal of Pharmaceutical and Clinical Research, 2018, 11, 40.	0.3	2
966	MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1. Molecular Medicine Reports, 2018, 19, 1331-1339.	2.4	12
967	Napsin A is negatively associated with EMT‑mediated EGFR‑TKI resistance in lung cancer cells. Molecular Medicine Reports, 2018, 18, 1247-1252.	2.4	3
968	Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients. Heliyon, 2018, 4, e01031.	3.2	13
969	Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells. Marine Drugs, 2018, 16, 506.	4.6	17
970	Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study. BMC Pulmonary Medicine, 2018, 18, 171.	2.0	7
971	GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors. Nature Communications, 2018, 9, 5154.	12.8	84
972	KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer. Frontiers in Oncology, 2018, 8, 384.	2.8	14
973	Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells. Oncotarget, 2018, 9, 16533-16546.	1.8	21
974	Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation. Hormones and Cancer, 2018, 9, 420-432.	4.9	25
975	MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non–small Cell Lung Cancers Expressing Wild-type <i>EGFR</i> Family Members. Clinical Cancer Research, 2018, 24, 6523-6535.	7.0	25
976	Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation. Scientific Reports, 2018, 8, 8216.	3.3	27

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
977	Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials. Lung Cancer, 2018, 122, 10-21.	2.0	22
978	Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients. Frontiers in Pharmacology, 2018, 9, 360.	3.5	9
979	Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial. BMC Cancer, 2018, 18, 598.	2.6	11
980	Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. Journal of Experimental and Clinical Cancer Research, 2018, 37, 140.	8.6	27
981	Overexpression of Napsin A resensitizes drug‑resistant lung cancer A549 cells to gefitinib by inhibiting EMT. Oncology Letters, 2018, 16, 2533-2538.	1.8	6
982	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 5094-5106.	0.9	47
983	Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes. International Journal of Biological Sciences, 2018, 14, 204-216.	6.4	75
984	Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor. Clinical Lung Cancer, 2018, 19, 518-530.e7.	2.6	48
985	Ferroptosis: A Novel Anti-tumor Action for Cisplatin. Cancer Research and Treatment, 2018, 50, 445-460.	3.0	449
987	Afatinib restrains K-RAS–driven lung tumorigenesis. Science Translational Medicine, 2018, 10, .	12.4	99
988	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. International Journal of Molecular Sciences, 2019, 20, 3951.	4.1	62
989	Oncogenic G12D mutation alters local conformations and dynamics of K-Ras. Scientific Reports, 2019, 9, 11730.	3.3	46
990	Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precision Clinical Medicine, 2019, 2, 100-109.	3.3	11
991	Analysis of the Target Genes of Transcription Factor ZNF536 in Lung Adenocarcinoma. , 2019, , .		1
992	RAS mutations in human cancers: Roles in precision medicine. Seminars in Cancer Biology, 2019, 59, 23-35.	9.6	85
993	<p>Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib</p> . Cancer Management and Research, 2019, Volume 11, 8937-8945.	1.9	9
994	The Metabolic Landscape of Lung Cancer: New Insights in a Disturbed Glucose Metabolism. Frontiers in Oncology, 2019, 9, 1215.	2.8	97
995	pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma. Communications Biology, 2019, 2, 334.	4.4	10

#	Article	IF	CITATIONS
996	FOSB–PCDHB13 Axis Disrupts the Microtubule Network in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 107.	3.7	17
997	A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer. Scientific Reports, 2019, 9, 648.	3.3	21
998	Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Experimental and Molecular Medicine, 2019, 51, 1-14.	7.7	97
999	Fluorescence polarization-based detection of cancer-related mutations using target-initiated rolling circle amplification. Analyst, The, 2019, 144, 4149-4152.	3.5	8
1000	Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors. Clinical Cancer Research, 2019, 25, 5984-5996.	7.0	46
1001	Deregulation of a Network of mRNA and miRNA Genes Reveals That CK2 and MEK Inhibitors May Synergize to Induce Apoptosis KRAS-Active NSCLC. Cancer Informatics, 2019, 18, 117693511984350.	1.9	6
1002	Clinical Impact of Rare and Compound Mutations of Epidermal Growth Factor Receptor in Patients With Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, 350-362.e4.	2.6	10
1003	Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling. Cells, 2019, 8, 442.	4.1	27
1004	Implementing Companion Diagnostic Testing in the Clinic. , 2019, , 413-427.		0
1005	Effect of Cetuximab and <i>EGFR</i> Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type <i>EGFR</i> and Use of <i>KRAS</i> as a Possible Biomarker for Treatment Responsiveness. Yonago Acta Medica, 2019, 62, 085-093.	0.7	4
1006	miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nature Metabolism, 2019, 1, 460-474.	11.9	57
1007	Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib. PLoS ONE, 2019, 14, e0213294.	2.5	5
1008	Association between the novel classification of lung adenocarcinoma subtypes and EGFR/KRAS mutation status: A systematic literature review and pooled-data analysis. European Journal of Surgical Oncology, 2019, 45, 870-876.	1.0	20
1009	An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer. , 2019, , 21-38.		1
1011	Oncogenèse pulmonaire: comprendre les addictions oncogéniques et les résistances. Revue Des Maladies Respiratoires Actualites, 2019, 11, 184-192.	0.0	0
1012	Current Approaches in NSCLC Targeting K-RAS and EGFR. International Journal of Molecular Sciences, 2019, 20, 5701.	4.1	47
1013	Research progress on the relationship between lung cancer drug-resistance and microRNAs. Journal of Cancer, 2019, 10, 6865-6875.	2.5	16
1014	Educational Case: Non-Small Cell Lung Cancer: Pathologic Diagnosis and Molecular Understanding. Academic Pathology, 2019, 6, 237428951988195.	1.1	1

#	ARTICLE	IF	Citations
1015	Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer. Antioxidants, 2019, 8, 603.	5.1	12
1016	Ultra-deep massively parallel sequencing with unique molecular identifier tagging achieves comparable performance to droplet digital PCR for detection and quantification of circulating tumor DNA from lung cancer patients. PLoS ONE, 2019, 14, e0226193.	2.5	18
1017	Diagnostic performance of F-18 FDG PET/CT for prediction of KRAS mutation in colorectal cancer patients: a systematic review and meta-analysis. Abdominal Radiology, 2019, 44, 1703-1711.	2.1	16
1018	Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Cancer Research, 2019, 79, 209-219.	0.9	56
1019	Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers. Cancer Letters, 2019, 442, 202-212.	7.2	12
1020	CLAmpâ€seq: A Novel Ampliconâ€Based NGS Assay with Concatemer Error Correction for Improved Detection of Actionable Mutations in Plasma cfDNA from Patients with NSCLC. Small Methods, 2020, 4, 1900357.	8.6	9
1021	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
1022	Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. International Journal of Surgical Pathology, 2020, 28, 51-59.	0.8	6
1023	Mutated RAS: Targeting the "Untargetable―with T Cells. Clinical Cancer Research, 2020, 26, 537-544.	7.0	25
1024	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.		117
1025	RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies. Critical Reviews in Oncology/Hematology, 2020, 146, 102859.	4.4	12
1026	Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice. Pharmacological Research, 2020, 161, 105183.	7.1	10
1028	A Genotype-Based Ensemble Classifier System for Non-Small-Cell Lung Cancer. IEEE Access, 2020, 8, 128509-128518.	4.2	0
1029	Genetic profile of nonâ€small cell lung cancer (NSCLC): A hospitalâ€based survey in Jinhua. Molecular Genetics & Genomic Medicine, 2020, 8, e1398.	1.2	10
1030	Expression of ATP/GTP Binding Protein 1 Has Prognostic Value for the Clinical Outcomes in Non-Small Cell Lung Carcinoma. Journal of Personalized Medicine, 2020, 10, 263.	2.5	1
1031	NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer. Cells, 2020, 9, 1830.	4.1	21
1032	SREBP1 regulates mitochondrial metabolism in oncogenic <i>KRAS</i> expressing NSCLC. FASEB Journal, 2020, 34, 10574-10589.	0.5	10
1033	Multiomics Reveals Ectopic ATP Synthase Blockade Induces Cancer Cell Death via a IncRNA-mediated Phospho-signaling Network. Molecular and Cellular Proteomics, 2020, 19, 1805-1825.	3.8	11

#	Article	IF	CITATIONS
1034	Identification of pan-cancer Ras pathway activation with deep learning. Briefings in Bioinformatics, 2021, 22, .	6.5	10
1035	Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR ^{WT} and EGFR ^{T790M} . Organic and Biomolecular Chemistry, 2020, 18, 7608-7634.	2.8	83
1036	<i>In silico</i> and saturation transfer differenceÂNMR approaches to unravel the binding mode of an andrographolide derivative to K-Ras oncoprotein. Future Medicinal Chemistry, 2020, 12, 1611-1631.	2.3	2
1037	Anlotinib can overcome acquired resistance to <scp>EGFRâ€TKIs</scp> via <scp>FGFR1</scp> signaling in nonâ€small cell lung cancer without harboring <scp>EGFR T790M</scp> mutation. Thoracic Cancer, 2020, 11, 1934-1943.	1.9	18
1038	Assessing the Current State of Lung Cancer Chemoprevention: A Comprehensive Overview. Cancers, 2020, 12, 1265.	3.7	13
1039	An <scp>EGFR</scp> signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. International Journal of Cancer, 2020, 147, 2621-2633.	5.1	13
1040	Integrating context of tumor biology and vaccine design to shape multidimensional immunotherapies. Future Drug Discovery, 2020, 2, FDD25.	2.1	1
1041	FKBP10 Regulates Protein Translation to Sustain Lung Cancer Growth. Cell Reports, 2020, 30, 3851-3863.e6.	6.4	19
1042	Cancer vaccines: Targeting KRAS-driven cancers. Expert Review of Vaccines, 2020, 19, 163-173.	4.4	30
1043	Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation. PLoS ONE, 2020, 15, e0230622.	2.5	41
1044	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 111-138.	2.8	27
1045	Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. Medicinal Research Reviews, 2020, 40, 2132-2176.	10.5	35
1046	Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR). Molecules, 2020, 25, 2914.	3.8	13
1047	<p>Biochemical Markers of Colorectal Cancer – Present and Future</p> . Cancer Management and Research, 2020, Volume 12, 4789-4797.	1.9	50
1048	Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients. Scientific Reports, 2020, 10, 2070.	3.3	13
1049	Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Scientific Reports, 2020, 10, 2707.	3.3	29
1050	The Biology of Lung Cancer. Clinics in Chest Medicine, 2020, 41, 25-38.	2.1	52
1051	KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. Cells, 2020, <u>9, 219.</u>	4.1	46

#	Article	IF	CITATIONS
1052	The apoptotic effect of GSK-3 inhibitors: BIO and CHIR 98014 on H1975 lung cancer cells through ROS generation and mitochondrial dysfunction. Biotechnology Letters, 2020, 42, 1351-1368.	2.2	4
1053	Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)—development and in-vitro efficacy. Drug Delivery and Translational Research, 2021, 11, 927-943.	5.8	34
1054	Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Cancer Discovery, 2021, 11, 384-407.	9.4	64
1055	Invasive mucinous adenocarcinoma of the lung arising in a type 1 congenital pulmonary airway malformation in a 68-year-old patient: a case report. Acta Chirurgica Belgica, 2021, 121, 55-60.	0.4	2
1056	Extended-spectrum of KRAS and NRAS mutations in lung cancer tissue specimens obtained with bronchoscopy. Indian Journal of Cancer, 2021, .	0.2	1
1057	Quinazolin-4(3 <i>H</i>)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 2055-2067.	5.2	7
1058	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2021, 2, 100186.	6.5	90
1059	Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2020, 10, 607840.	2.8	10
1060	Therapeutic Strategies Targeting Signaling Pathways in Lung Cancer. , 2021, , 217-239.		1
1062	Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy. Frontiers in Oncology, 2021, 11, 621992.	2.8	13
1063	A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma. Pharmaceuticals, 2021, 14, 256.	3.8	6
1064	Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells. Cancers, 2021, 13, 1205.	3.7	25
1067	Development of a new genetic reference material system based on Saccharomyces cerevisiae cells. Molecular Therapy - Methods and Clinical Development, 2021, 20, 473-482.	4.1	1
1068	Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer. Clinical Cancer Research, 2021, 27, 4012-4024.	7.0	20
1069	The importance of Ras in drug resistance in cancer. British Journal of Pharmacology, 2022, 179, 2844-2867.	5.4	26
1070	Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers. Journal of Biomedical Science, 2021, 28, 24.	7.0	20
1071	Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib‑resistant non‑small cell lung cancer cells. Oncology Letters, 2021, 22, 556.	1.8	12
1072	Interaction of FLNA and ANXA2 promotes gefitinib resistance by activating the Wnt pathway in non-small-cell lung cancer. Molecular and Cellular Biochemistry, 2021, 476, 3563-3575.	3.1	9

#	Article	IF	CITATIONS
1073	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells, 2021, 10, 1206.	4.1	17
1074	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. Translational Oncology, 2021, 14, 101056.	3.7	17
1075	Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools. Scientific Reports, 2021, 11, 10761.	3.3	24
1076	Recent Advances in Curcumin Treated Non-Small Cell Lung Cancers: An Impetus of Pleiotropic Traits and Nanocarrier Aided Delivery. Current Medicinal Chemistry, 2021, 28, 3061-3106.	2.4	6
1077	Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma. Oncology Reports, 2021, 46, .	2.6	22
1078	EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 2021, 13, 2748.	3.7	148
1079	Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). Scientific Reports, 2021, 11, 15112.	3.3	2
1080	The Importance of Being PI3K in the RAS Signaling Network. Genes, 2021, 12, 1094.	2.4	28
1081	Calling Attention to the Role of Race-Driven Societal Determinants of Health on Aggressive Tumor Biology: A Focus on Black Americans. JCO Oncology Practice, 2022, 18, 15-22.	2.9	17
1082	JunD, not c-Jun, is the AP-1 transcription factor required for Ras-induced lung cancer. JCI Insight, 2021, 6, .	5.0	22
1083	Paradigm shift in the management of metastatic nonsmall cell lung cancer. International Journal of Clinical Practice, 2021, 75, e14533.	1.7	0
1084	Angiogenic activities are increased via upregulation of HIF‑1α expression in gefitinib‑resistant non‑small cell lung carcinoma cells. Oncology Letters, 2021, 22, 671.	1.8	2
1085	Machine Learning-Based Radiomics Signatures for EGFR and KRAS Mutations Prediction in Non-Small-Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 9254.	4.1	71
1086	K-RAS4A: Lead or Supporting Role in Cancer Biology?. Frontiers in Molecular Biosciences, 2021, 8, 729830.	3.5	5
1087	Immuneâ€related eightâ€IncRNA signature for improving prognosis prediction of lung adenocarcinoma. Journal of Clinical Laboratory Analysis, 2021, 35, e24018.	2.1	13
1088	Frequently used quantitative polymerase chain reaction–based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas. Human Pathology, 2021, 115, 67-75	2.0	2
1089	Infrequent RAS mutation is not associated with specific histological phenotype in gliomas. BMC Cancer, 2021, 21, 1025.	2.6	6
1090	Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations. Anticancer Research, 2021, 41, 4807-4820.	1.1	2

#	Article	IF	CITATIONS
1091	Pulmonary Inflammation and KRAS Mutation in Lung Cancer. Advances in Experimental Medicine and Biology, 2021, 1303, 71-87.	1.6	4
1092	Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treatment and Research Communications, 2021, 27, 100342.	1.7	5
1093	My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype. Genome Biology, 2021, 22, 53.	8.8	11
1094	Two Birds with a Stone: Molecular Cancer Therapy Targeting Signal Transduction and DNA Repair Pathways. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 163-186.	0.1	1
1095	Expression and prognostic significance of the EGFR in solid tumors. , 2008, , 210-223.		1
1096	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
1097	Identifying Critical Signaling Molecules for the Treatment of Cancer. , 2007, 172, 5-24.		3
1098	Genomic Pathology of Lung Cancer. , 2013, , 1-46.		1
1099	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. , 2008, , 1307-1366.		7
1100	Cancer of the Lung. , 2014, , 1143-1192.e13.		5
1101	Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines. Scientific Reports, 2020, 10, 959.	3.3	28
1102	The K-Ras effector p38Î ³ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. Journal of Biological Chemistry, 2017, 292, 15070-15079.	3.4	10
1103	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non???Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology, 2006, 1, 52-60.	1.1	13
1104	The Role of Gefitinib Treatment for Korean Never-Smokers with Advanced or Metastatic Adenocarcinoma of the Lung: A Prospective Study. Journal of Thoracic Oncology, 2006, 1, 965-971.	1.1	33
1105	Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria. Journal of Thoracic Oncology, 2006, 1, S13-S19.	1.1	106
1108	Oncogenes Come of Age. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 1-9.	1.1	27
1109	Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 483-488.	1.1	7
1110	EGFR and K-ras Mutation Analysis in Non-Small Cell Lung Cancer: Comparison of Paraffin Embedded versus Frozen Specimens. Analytical Cellular Pathology, 2007, 29, 257-264.	1.4	53

#	Article	IF	CITATIONS
1111	Why targeted therapy hasn't worked in advanced cancer. Journal of Clinical Investigation, 2007, 117, 2762-2765.	8.2	18
1112	Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions. Journal of Clinical Investigation, 2009, 119, 1727-1740.	8.2	230
1113	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Journal of Clinical Investigation, 2011, 121, 4311-4321.	8.2	177
1114	Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. Journal of Clinical Investigation, 2012, 122, 2637-2651.	8.2	79
1115	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. Journal of Clinical Investigation, 2014, 124, 3003-3015.	8.2	84
1116	Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. PLoS ONE, 2011, 6, e20351.	2.5	338
1117	Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR. PLoS ONE, 2011, 6, e25191.	2.5	96
1118	Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e64816.	2.5	71
1119	EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e72966.	2.5	11
1120	DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma. PLoS ONE, 2013, 8, e79526.	2.5	12
1121	Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel. PLoS ONE, 2013, 8, e80478.	2.5	96
1122	Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments. PLoS ONE, 2015, 10, e0128360.	2.5	23
1123	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS ONE, 2015, 10, e0143333.	2.5	21
1124	The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma. PLoS ONE, 2017, 12, e0177822.	2.5	5
1125	TW37 enhances the pro-apoptosis and anti-migration ability of gefitinib in Non-Small Cell Lung Cancer. Cellular and Molecular Biology, 2018, 64, 6-10.	0.9	7
1126	Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer. Bosnian Journal of Basic Medical Sciences, 2021, 21, 198-207.	1.0	5
1127	Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC. Oncotarget, 2017, 8, 179-190.	1.8	31
1128	Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors. Oncotarget, 2016, 7, 57752-57769.	1.8	27

#	Article	IF	CITATIONS
1129	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab. Oncotarget, 2016, 7, 68111-68121.	1.8	16
1130	Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma. Oncotarget, 2016, 7, 73664-73680.	1.8	14
1131	Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. Oncotarget, 2017, 8, 52792-52801.	1.8	32
1132	KRAS-driven miR-29b expression is required for tumor suppressor gene silencing. Oncotarget, 2017, 8, 74755-74766.	1.8	3
1133	Super enhancer associated <i>RAI14</i> is a new potential biomarker in lung adenocarcinoma. Oncotarget, 2017, 8, 105251-105261.	1.8	15
1134	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget, 2014, 5, 8937-8946.	1.8	6
1135	Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer. Oncotarget, 2011, 2, 165-177.	1.8	52
1136	Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. Oncotarget, 2018, 9, 22243-22253.	1.8	15
1137	BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications. Oncotarget, 2014, 5, 11752-11777.	1.8	83
1138	Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade. Oncotarget, 2015, 6, 20132-20144.	1.8	8
1139	Putative effectors for prognosis in lung adenocarcinoma are ethnic and gender specific. Oncotarget, 2015, 6, 19483-19499.	1.8	4
1140	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. Oncotarget, 2015, 6, 26090-26103.	1.8	37
1141	<i>KRAS</i> mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget, 2016, 7, 8373-8388.	1.8	73
1142	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. Oncotarget, 2016, 7, 21496-21509.	1.8	20
1143	Nitrilase 1 modulates lung tumor progression <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2016, 7, 21381-21392.	1.8	5
1144	Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. Journal of Experimental Pharmacology, 2011, 3, 21.	3.2	4
1145	Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers. Current Topics in Medicinal Chemistry, 2019, 19, 2128-2142.	2.1	9
1146	Targeting Mutant KRAS for Anticancer Therapy. Current Topics in Medicinal Chemistry, 2019, 19, 2098-2113.	2.1	12

#	Article	IF	CITATIONS
1147	Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 671-677.	1.1	4
1148	Bioinformatics approach for the validation of non-small cell lung cancer biomarkers. Frontiers in Bioscience - Elite, 2011, E3, 46-50.	1.8	6
1149	A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cellular Oncology, 2009, 31, 161-7.	1.9	23
1152	PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants. International Journal of Oncology, 2020, 57, 989-1000.	3.3	4
1153	GLI1 activation is a key mechanism of erlotinib resistance in human non‑small cell lung cancer. Oncology Letters, 2020, 20, 76.	1.8	8
1154	Thymic neoplasm: a rare disease with a complex clinical presentation. Journal of Thoracic Disease, 2013, 5, 173-83.	1.4	24
1155	Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification. Journal of Thoracic Disease, 2014, 6, S502-25.	1.4	13
1156	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Translational Lung Cancer Research, 2015, 4, 36-54.	2.8	499
1157	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Translational Lung Cancer Research, 2015, 4, 67-81.	2.8	241
1158	Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. Journal of Nucleic Acids Investigation, 2010, 1, 10.	0.8	2
1159	Targeted therapies in development for non-small cell lung cancer. Journal of Carcinogenesis, 2013, 12, 22.	2.5	67
1160	Targeted therapy in nonsmall cell lung cancer. Indian Journal of Cancer, 2017, 54, 83.	0.2	6
1161	Predictive Significance of KRAS and Tau for Chemoresponse in Advanced Non-Small-Cell Lung Cancer. Korean Journal of Pathology, 2009, 43, 435.	1.3	1
1162	About the Feasibility of Personalized Medicine in a Low Income Country?. Open Journal of Social Sciences, 2015, 03, 41-45.	0.3	2
1163	The future of anti-EGFR therapy. International Journal of Biological Markers, 2007, 22, 88-93.	1.8	3
1164	Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. International Journal of Biological Markers, 2007, 22, 10-23.	1.8	5
1165	Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. World Journal of Clinical Oncology, 2014, 5, 806.	2.3	22
1166	Non-small cell lung cancer - genetic predictors. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2013, 157, 125-136.	0.6	34

#	Article	IF	CITATIONS
1167	Correlation of genes associated with drug response to prognosis of large cell lung carcinoma. Chinese Journal of Cancer, 2011, 30, 497-504.	4.9	5
1168	Molecular Diagnostics of Lung Carcinomas. Archives of Pathology and Laboratory Medicine, 2011, 135, 622-629.	2.5	30
1169	Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma. Journal of Cancer Research Updates, 2013, 2, 265-282.	0.3	53
1170	Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics, 2012, 67, 419-424.	1.5	41
1171	Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4485-4494.	1.2	16
1172	Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4147-4156.	1.2	34
1173	Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4759-4768.	1.2	5
1174	In silico-guided sequence modifications of K-ras epitopes improve immunological outcome against G12V and G13D mutant <i>KRAS</i> antigens. PeerJ, 2018, 6, e5056.	2.0	9
1175	Driver gene alterations profiling of Chinese nonâ€small cell lung cancer and the effects of coâ€occurring alterations on immunotherapy. Cancer Medicine, 2021, 10, 7360-7372.	2.8	5
1176	Mutations in the Epidermal Growth Factor Receptor Gene And Sensitivity to Tyrosine Kinase Inhibitors. Japanese Journal of Lung Cancer, 2006, 46, 237-240.	0.1	0
1177	Epidermal Growth Factor Receptor Targeted Therapy—Markers of Sensitivity and Response. Translational Medicine Series, 2007, , 97-122.	0.0	0
1179	Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. , 2007, , 19-44.		2
1180	Cellular sensitivity to EGF receptor inhibitors. , 2008, , 340-355.		0
1181	Response to Conventional Therapy and Targeted Molecular Therapy. Molecular Pathology Library, 2008, , 226-232.	0.1	0
1182	The intersection of EGFR and the Ras signaling pathway. , 2008, , 84-90.		1
1183	Epidermal Growth Factor Receptor Mutations and Sensitivity to Selective Kinase Inhibitors in Human Lung Cancer. , 2008, , 103-126.		0
1184	EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. , 2008, , 281-324.		0
1185	Targeting Signaling Pathways in Cancer Therapy. , 2009, , 309-326.		0

#	Article	IF	CITATIONS
1186	Biomarkers of Sensitivity for the Treatment of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer. Japanese Journal of Lung Cancer, 2009, 49, 934-938.	0.1	0
1187	Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients. Korean Journal of Pathology, 2009, 43, 509.	1.3	0
1188	Clinical Analysis of 24 Cases Treated Twice or More with Gefitinib for Recurrent Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2009, 49, 831-835.	0.1	0
1189	Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib. Archives of Pathology and Laboratory Medicine, 2009, 133, 470-477.	2.5	42
1190	Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. OncoTargets and Therapy, 2009, 2, 251.	2.0	1
1191	Pharmacogenetics in Lung Cancer. , 2010, , 87-99.		0
1192	Carcinogenesis of Lung Cancer. , 2010, , 203-212.		0
1193	Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer. , 2010, , 205-226.		2
1194	Apoptosis Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2010, , 369-386.		0
1195	DNA Biomarkers in the Diagnosis and Management of Cancer. , 2010, , 165-184.		0
1196	Abstract PL2-1: The impact of genomic changes on the treatment of lung cancer. , 2010, , .		0
1197	Facteurs prédictifs pour un traitement personnalisé des cancers bronchiques non à petites cellules. , 2011, , 103-125.		0
1198	The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies. , 2011, , 33-53.		0
1199	Accuracy of Cytology Specimen and Needle Core Biopsies for Detection of KRAS Mutation in Non-Small Cell Carcinoma: Comparison With Resection Specimen. World Journal of Oncology, 2011, 2, 275-280.	1.5	2
1200	Genotyping non-small cell lung cancer (NSCLC) in Latin America (LATAM) Journal of Clinical Oncology, 2011, 29, e21155-e21155.	1.6	0
1201	Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine. , 2012, , 569-589.		1
1203	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
1204	Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .	0.4	0

#	Article	IF	CITATIONS
1205	Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. , 2014, , 75-118.		0
1206	Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50.		0
1207	Molecular Testing in Pulmonary Tumors. , 2014, , 211-228.		0
1208	Transitioning Diagnostic Molecular Pathology to the Genomic Era: Cancer Somatic Mutation Panel Testing. , 2014, , 3-13.		0
1209	Personalized treatment options in Non-small Cell Lung Cancer. Receptors & Clinical Investigation, 0, , .	0.9	0
1210	Strategy on Patients with EGFR Mutation. , 2015, , 133-145.		0
1212	CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. F1000Research, 2015, 4, 160.	1.6	2
1213	CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons. F1000Research, 2015, 4, 160.	1.6	2
1215	Oncogenes and the Initiation and Maintenance of Tumorigenesis. , 2017, , 143-157.		1
1217	Dual-targeting of MEK and CDK4/6 in KRAS-mutated Non-Small Cell Lung Cancer. Science Proceedings, 0, 4, .	0.0	0
1218	KRAS-Mutated Lung Cancer. Current Cancer Research, 2019, , 195-216.	0.2	0
1219	Lung and Respiratory Tract Cytology. , 2020, , 95-117.		0
1220	Liquid Biopsy to Characterize Cell-Free DNA in Cancer Detection and Monitoring. Research and Development on Information and Communication Technology, 2019, 2019, 93-98.	0.4	0
1221	Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma. Cancers, 2021, 13, 5471.	3.7	18
1222	Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management. Journal of Personalized Medicine, 2021, 11, 1102.	2.5	40
1223	Molecular and Biological Basis of Lung Cancer-Part I. , 2020, 01, .		0
1225	Intertumoural Heterogeneity and Branch Evolution of Synchronous Multiple Primary Lung Adenocarcinomas by Next-Generation Sequencing Analysis. Frontiers in Oncology, 2021, 11, 760715.	2.8	1
1226	Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC. International Journal of Oncology, 2020, 57, 939-955.	3.3	3

	Сітат	ion Report	
#	Article	IF	CITATIONS
1227	Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. , 2008, , 291-306.		0
1228	Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. , 2008, , 307-316.		1
1229	Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation. , 2008, , 371-387.		0
1230	Molecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancer. Cancer Biology and Medicine, 2012, 9, 18-22.	3.0	8
1231	The Molecular Genetics of Lung Cancer. , 0, , 61-83.		24
1233	A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer. International Journal of Oncology, 2010, 36, 19-27.	3.9	4
1234	Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. International Journal of Clinical and Experimental Pathology, 2011, 4, 403-9.	0.5	3
1235	Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. International Journal of Clinical and Experimental Pathology, 2013, 6, 1880-9.	0.5	24
1237	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. Journal of Thoracic Disease, 2014, 6, S568-80.	1.4	10
1238	ZEPHYR illustrates the perils of testing targeted treatments in unselected non-small-cell lung cancer patients. Translational Lung Cancer Research, 2013, 2, E1-3.	2.8	0
1239	Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biology and Medicine, 2015, 12, 126-39.	3.0	20
1240	Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. American Journal of Cancer Research, 2015, 5, 2531-61.	1.4	50
1241	Lipophilic bisphosphonates plus rapamycin: a deadly combination for KRAS-mutated lung adenocarcinoma. Annals of Translational Medicine, 2015, 3, 289.	1.7	0
1242	Drug resistance in lung cancer. Lung Cancer: Targets and Therapy, 2010, 1, 23-36.	2.7	59
1243	Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery. Journal of Radiosurgery and SBRT, 2015, 3, 171-178.	0.2	2
1250	Targeting snoRNAs as an emerging method of therapeutic development for cancer. American Journal of Cancer Research, 2019, 9, 1504-1516.	1.4	5
1251	Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188645.	7.4	52
1252	Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer. European Journal of Cancer, 2022, 160, 189-205.	2.8	9

#	Article	IF	Citations
1253	Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. Genome Medicine, 2022, 14, 3.	8.2	16
1254	Deciphering Genetic Alterations of Taiwanese Patients with Pancreatic Adenocarcinoma through Targeted Sequencing. International Journal of Molecular Sciences, 2022, 23, 1579.	4.1	2
1255	The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures. Frontiers in Oncology, 2021, 11, 792385.	2.8	1
1256	Anticancer drug resistance: An update and perspective. Drug Resistance Updates, 2021, 59, 100796.	14.4	122
1257	α-Fetoprotein-Producing Endometrial Carcinoma Is Associated With Fetal Gut-Like and/or Hepatoid Morphology, Lymphovascular Infiltration, TP53 Abnormalities, and Poor Prognosis: Five Cases and Literature Review. Frontiers in Medicine, 2021, 8, 799163.	2.6	7
1258	Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology. ELife, 2021, 10, .	6.0	16
1259	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 869672.	2.8	30
1260	Synthesis and Biological Activity of 3,9-Diazatetraasteranes as Novel EGFR Tyrosine Kinase Inhibitors. Russian Journal of General Chemistry, 2022, 92, 446-456.	0.8	5
1261	TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy. Frontiers in Oncology, 2022, 12, 860563.	2.8	12
1262	MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 13357.	4.1	6
1263	A Six-Gene Prognostic and Predictive Radiotherapy-Based Signature for Early and Locally Advanced Stages in Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 2054.	3.7	4
1264	Highly Potent, Selective, Biostable, and Cell-Permeable Cyclic <scp>d</scp> -Peptide for Dual-Targeting Therapy of Lung Cancer. Journal of the American Chemical Society, 2022, 144, 7117-7128.	13.7	19
1265	Deregulated signaling networks in lung cancer. , 0, , 421-442.		0
1266	Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. , 0, , 499-517.		0
1271	Epidermal Growth Factor Receptor Inhibitors. , 0, , 352-368.		0
1272	From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy. Tumori, 2011, 97, 160-5.	1.1	8
1282	Phase III design: principles. Chinese Clinical Oncology, 2016, 5, 10.	1.2	3
1285	New pyrimidine-5-carbonitrile derivatives as EGFR inhibitors with anticancer and apoptotic activities: design, molecular modeling and synthesis. New Journal of Chemistry, 2022, 46, 11812-11827.	2.8	3

#	Article	IF	CITATIONS
1286	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors. Cancers, 2022, 14, 2202.	3.7	3
1287	A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188751.	7.4	1
1288	Asymmetric Total Synthesis of Eupalinilide E, a Promoter of Human HSPC Expansion. Organic Letters, 2022, 24, 4745-4749.	4.6	7
1289	Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1053-1076.	5.2	16
1290	Differences in actionable genomic alterations between brain metastases and non‑brain metastases in patients with non‑small cell lung cancer. International Journal of Oncology, 2022, 61, .	3.3	1
1291	International co-validation on absolute quantification of single nucleotide variants of KRAS by digital PCR. Analytical and Bioanalytical Chemistry, 2022, 414, 5899-5906.	3.7	2
1292	Genomic Features of Organ-Specific Metastases in Lung Adenocarcinoma. Frontiers in Oncology, 0, 12, .	2.8	1
1294	Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature. International Cancer Conference Journal, 2022, 11, 231-237.	0.5	3
1295	Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. Cancers, 2022, 14, 4103.	3.7	14
1296	Quo vadis, Chirurgie?. Der Merkurstab, 2022, 75, 272-278.	0.1	0
1296 1297	Quo vadis, Chirurgie?. Der Merkurstab, 2022, 75, 272-278. SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14.	0.1	0
1296 1297 1298	Quo vadis, Chirurgie?. Der Merkurstab, 2022, 75, 272-278. SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14. The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013â€"2018). International Journal of Environmental Research and Public Health, 2022, 19, 11027.	0.1 1.9 2.6	0 2 4
1296 1297 1298 1299	Quo vadis, Chirurgie?. Der Merkurstab, 2022, 75, 272-278. SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14. The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013–2018). International Journal of Environmental Research and Public Health, 2022, 19, 11027. Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as Potential Inhibitors of Epidermal Growth Factor Receptor. Letters in Drug Design and Discovery, 2024, 21, 552-558.	0.1 1.9 2.6 0.7	0 2 4 0
1296 1297 1298 1299 1300	Quo vadis, Chirurgie?. Der Merkurstab, 2022, 75, 272-278. SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/ECFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14. The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013à€"2018). International Journal of Environmental Research and Public Health, 2022, 19, 11027. Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as Potential Inhibitors of Epidermal Crowth Factor Receptor. Letters in Drug Design and Discovery, 2024, 21, 552-558. NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. Cancers, 2022, 14, 4395.	0.1 1.9 2.6 0.7 3.7	0 2 4 0
1296 1297 1298 1299 1300	Quo vadis, Chirurgie?. Der Merkurstab, 2022, 75, 272-278.SH00557 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14.The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013à€"2018). International Journal of Environmental Research and Public Health, 2022, 19, 11027.Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as Potential Inhibitors of Epidermal Growth Factor Receptor. Letters in Drug Design and Discovery, 2024, 21, 552-558.NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. Cancers, 2022, 14, 4395.Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 0, 12, .	0.1 1.9 2.6 0.7 3.7 2.8	0 2 4 0 5 3
1296 1297 1298 1299 1300 1301	Quo vadis, Chirurgie?. Der Merkurstab, 2022, 75, 272-278. SH00557 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/ECFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14. The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013–2018). International Journal of Environmental Research and Public Health, 2022, 19, 11027. Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as Potential Inhibitors of Epidermal Growth Factor Receptor. Letters in Drug Design and Discovery, 2024, 21, 552-558. NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. Cancers, 2022, 14, 4395. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 0, 12, . Computational Intelligence in Drug Discovery for Non-small Cell Lung Cancer. Brain Informatics and Health, 2022, 63-92.	0.1 1.9 2.6 0.7 3.7 2.8	0 2 4 0 5 3
1296 1297 1298 1299 1300 1301 1302	Quo vadis, Chirurgie?. Der Merkurstab, 2022, 75, 272-278. SH005557 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/ECFR/HER3 Inhibition. BioMed Research International, 2022, 2022, 1-14. The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013âC"2018). International Journal of Environmental Research and Public Health, 2022, 19, 11027. Synthesis and Biological Evaluation of 3,9-Dioxatetraasteranes as Potential Inhibitors of Epidermal Growth Factor Receptor. Letters in Drug Design and Discovery, 2024, 21, 552-558. NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma. Cancers, 2022, 14, 4395. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Frontiers in Oncology, 0, 12, . Computational Intelligence in Drug Discovery for Non-small Cell Lung Cancer. Brain Informatics and Health, 2022, 63-92. Somatic mutations in colorectal cancer: regional experience. Consilium Medicum, 2022, 24, 291-296.	0.1 1.9 2.6 0.7 3.7 2.8 0.4	0 2 4 0 5 3 0

#	Article	IF	CITATIONS
1305	CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics Modeling. Cancers, 2022, 14, 6224.	3.7	4
1306	Extensive genomic analysis in patients with <i>KRAS</i> -mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact. Acta Oncológica, 2022, 61, 1499-1506.	1.8	0
1307	Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer. Advances in Cancer Research, 2023, , 163-198.	5.0	0
1308	Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. IScience, 2023, 26, 106082.	4.1	2
1309	Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. Journal of Medicinal Chemistry, 2023, 66, 3135-3172.	6.4	6
1310	Differences of genomic alterations and heavy metals in non-small cell lung cancer with different histological subtypes. Journal of Cancer Research and Clinical Oncology, 2023, 149, 9999-10013.	2.5	1
1311	Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer. , 2015, 1, 20-25.		0
1312	Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRASâ€mutant human lung cancer cells. Molecular Carcinogenesis, 2023, 62, 1136-1146.	2.7	3
1313	Mathematical modeling the order of driver gene mutations in colorectal cancer. PLoS Computational Biology, 2023, 19, e1011225.	3.2	2
1314	Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations. Computers in Biology and Medicine, 2023, 163, 107204.	7.0	0
1315	Brain metastasis screening in the molecular age. Neuro-Oncology Advances, 2023, 5, .	0.7	0
1316	Deciphering and identifying pan-cancer RAS pathway activation based on graph autoencoder and ClassifierChain. Electronic Research Archive, 2023, 31, 4951-4967.	0.9	0
1317	A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer, 2023, 183, 107313.	2.0	0
1318	Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer. Pharmaceuticals, 2023, 16, 1042.	3.8	1
1319	<i>NF1</i> alterations in cancers: therapeutic implications in precision medicine. Expert Opinion on Investigational Drugs, 2023, 32, 941-957.	4.1	2
1322	Lung cancer organoids: models for preclinical research and precision medicine. Frontiers in Oncology, 0, 13, .	2.8	0
1323	An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health. Applied Biochemistry and Biotechnology, 0, , .	2.9	0
1324	Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives as novel anti-cancer, dual EGFR ^{WT} /COX-2 inhibitors with docking studies. RSC Advances, 2023, 13, 32296-32320.	3.6	1

#	Article	IF	CITATIONS
1325	Non-Small Cell Lung Cancer Genotype Prediction Utilizing Multiparametric Artificial Intelligence Investigations. Academic Radiology, 2024, 31, 684-685.	2.5	0
1326	Benefits of Implementing Reflex Genomic Analysis for Nonsmall Cell Lung Cancer. journal of applied laboratory medicine, The, 2024, 9, 28-40.	1.3	0
1328	Adaptation of a mutual exclusivity framework to identify driver mutations within oncogenic pathways. American Journal of Human Genetics, 2024, 111, 227-241.	6.2	0
1329	Multisequence MRI-based radiomics signature as potential biomarkers for differentiating KRAS mutations in non-small cell lung cancer with brain metastases. European Journal of Radiology Open, 2024, 12, 100548.	1.6	0
1330	Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy. Frontiers in Oncology, 0, 14, .	2.8	0
1331	Tumorigenicity and prediction of clinical prognosis of patientâ€derived gastric cancer organoids. Clinical and Translational Medicine, 2024, 14, .	4.0	0